# Centers for Disease Control and Prevention Model Performance Evaluation Program T-Lymphocyte Immunophenotyping (TLI) 

Figures and Tables Used for the Analysis of Participant Laboratory Results for the

September 1996 Shipment

## U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service
Centers for Disease Control and Prevention
Public Health Practice Program Office
Division of Laboratory Systems
Atlanta, Georgia 30333

Use of trade names is for identification only and does not constitute endorsement by the Public Health Service or by the U.S. Department of Health and Human Services.

Figures and Tables Used for the Analysis of the September 1996 Specimen Shipment Results Submitted by Laboratories Participating in the Model Performance
Evaluation Program for T-Lymphocyte Immunophenotyping
Production of this report was coordinated in CDC by:
Public Health Practice Program Office . . . . . . . . . . . Edward L. Baker, M.D., M.P.H.
Director
Division of Laboratory Systems . . . . . . . . . . . . . . . . Carlyn L. Collins, M.D., M.P.H.
Director
Laboratory Practice Assessment Branch . . . . . . . . . . . . . . . Thomas L. Hearn, Ph.D.
Chief
The material in this report was developed and prepared by:
Model Performance Evaluation Program (MPEP) . . . . . . . William O. Schalla, M.S. Chief
MPEP TLI Performance Evaluation . . . . . . . . . . . . . . . . . . . . G. David Cross, M.S. MPEP TLI Project Coordinator

Information about this report should be addressed to the Model Performance Evaluation Program by calling (770) 488-4559 or (770) 488-4366.

# Centers for Disease Control and Prevention (CDC) - Model Performance Evaluation Program for T-Lymphocyte Immunophenotyping (TLI) <br> Donor Specimen Identification for September 10, 1996 TLI Shipment Specimens 

| Panel | Participant Lab | CDC Donor |
| :--- | :---: | :---: |
| Letter | Vial Label | Number |

Donor Information<br>(HIV-1 ${ }^{\text {a }}$ status and CD4 ${ }^{+}$cell count)

| A | A1, A5 | 01 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
| :---: | :---: | :---: | :---: |
|  | A2 | 08 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$ |
|  | A3 | 12 | HIV-1 Antibody-Negative |
|  | A4 | 13 | HIV-1 Antibody-Negative |
| B | B1 | 09 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$ |
|  | B2 | 13 | HIV-1 Antibody-Negative |
|  | B3, B4 | 02 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count > 200 but < 500 |
|  | B5 | 14 | HIV-1 Antibody-Negative |
| C | C1, C2 | 03 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
|  | C3 | 15 | HIV-1 Antibody-Negative |
|  | C4 | 12 | HIV-1 Antibody-Negative |
|  | C5 | 10 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$ |
| D | D1 | 12 | HIV-1 Antibody-Negative |
|  | D2, D4 | 04 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
|  | D3 | 08 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$ |
|  | D5 | 13 | HIV-1 Antibody-Negative |
| E | E1 | 13 | HIV-1 Antibody-Negative |
|  | E2 | 15 | HIV-1 Antibody-Negative |
|  | E3 | 09 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$ |
|  | E4, E5 | 05 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
| F | F1 | 14 | HIV-1 Antibody-Negative |
|  | F2, F3 | 06 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
|  | F4 | 10 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$ |
|  | F5 | 12 | HIV-1 Antibody-Negative |
| G | G1 | 14 | HIV-1 Antibody-Negative |
|  | G2, G4 | 07 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count count > 200 but < 500 |
|  | G3 | 15 | HIV-1 Antibody-Negative |
|  | G5 | 11 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$ |

${ }^{\text {a }}$ Human immunodeficiency virus type 1

# Centers for Disease Control and Prevention (CDC) - Model Performance Evaluation Program for T-Lymphocyte Immunophenotyping (TLI) <br> Donor Specimen Identification for September 17, 1996 TLI Shipment Specimens 

| Panel | Participant Lab | CDC Donor |
| :--- | :---: | :---: |
| Letter | Vial Label | Number |

## Donor Information <br> (HIV-1 ${ }^{\text {a }}$ status and CD4 ${ }^{+}$cell count)

| H | H1 | 24 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$ |
| :---: | :---: | :---: | :---: |
|  | H2 | 29 | HIV-1 Antibody-Negative |
|  | H3, H5 | 17 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
|  | H4 | 28 | HIV-1 Antibody-Negative |
| I | I1, I4 | 18 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
|  | I2 | 27 | HIV-1 Antibody-Negative |
|  | I3 | 25 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count > 200 but < 500 |
|  | I5 | 30 | HIV-1 Antibody-Negative |
| J | J1 | 23 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$ |
|  | J2 | 28 | HIV-1 Antibody-Negative |
|  | J3, J5 | 19 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
|  | J4 | 27 | HIV-1 Antibody-Negative |
| K | K1, K5 | 20 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
|  | K2 | 24 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$ |
|  | K3 | 29 | HIV-1 Antibody-Negative |
|  | K4 | 28 | HIV-1 Antibody-Negative |
| L | L1 | 25 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count > 200 but < 500 |
|  | L2, L5 | 21 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
|  | L3 | 27 | HIV-1 Antibody-Negative |
|  | L4 | 30 | HIV-1 Antibody-Negative |
| M | M1 | 23 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$ |
|  | M2 | 27 | HIV-1 Antibody-Negative |
|  | M3, M5 | 16 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
|  | M4 | 28 | HIV-1 Antibody-Negative |
| N | N1, N4 | 22 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$ |
|  | N2 | 26 | HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$ |
|  | N3 | 29 | HIV-1 Antibody-Negative |
|  | N5 | 30 | HIV-1 Antibody-Negative |

${ }^{\text {a }}$ Human immunodeficiency virus type 1

# Centers for Disease Control and Prevention (CDC) - Model Performance Evaluation Program for T-Lymphocyte Immunophenotyping (TLI) <br> Donor Specimen Identification for September 24, 1996 TLI Shipment Specimens 

| Panel | Participant Lab |
| :--- | :---: |
| Letter | Vial Label |


| O | O1 | 44 |
| :--- | :--- | :--- |
|  | O2, 03 | 33 |
|  | O4 | 42 |
|  | O5 | 40 |
| P | P1, P3 | 34 |
|  | P2 | 43 |
|  | P4 | 38 |
|  | P5 | 42 |
| Q | Q1 |  |
|  | Q2, Q4 | 39 |
|  | Q3 | 35 |
|  | Q5 | 45 |
|  |  | 43 |

R R1, R5 36

R2 40
R3 42
R4 45

S S1, S5 31
S2
S3
S4 38

| T | T1 | 43 |
| :--- | :--- | :--- |
|  | T2 | 39 |
|  | T3, T4 | 32 |
|  | T5 | 44 |
|  |  |  |
| U | U1 | 44 |
|  | U2 | 41 |
|  | U3 | 45 |
|  | U4, U5 | 37 |

42
43

## CDC Donor <br> Number

44
33
42
40

34
43
38
42

39
35
45
43

36

45
14238

43
39
32
44
44
41
45
37

## Donor Information <br> (HIV-1 ${ }^{\text {a }}$ status and CD4 ${ }^{+}$cell count)

HIV-1 Antibody-Negative
HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$
HIV-1 Antibody-Negative
HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$
HIV-1 Antibody-Positive, $\mathrm{CD}^{+}$count $\geq 500$
HIV-1 Antibody-Negative
HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$
HIV-1 Antibody-Negative
HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$
HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$
HIV-1 Antibody-Negative
HIV-1 Antibody-Negative
HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$
HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$
HIV-1 Antibody-Negative
HIV-1 Antibody-Negative
HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$
HIV-1 Antibody-Negative
HIV-1 Antibody-Negative
HIV-1 Antibody-Positive, $\mathrm{CD}^{+}$count $\leq 200$
HIV-1 Antibody-Negative
HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$
HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$
HIV-1 Antibody-Negative
HIV-1 Antibody-Negative
HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\leq 200$
HIV-1 Antibody-Negative
HIV-1 Antibody-Positive, CD4 ${ }^{+}$count $\geq 500$
${ }^{\text {a }}$ Human immunodeficiency virus type 1

Figure 1. Primary classification of laboratories participating in the September 1996 shipment.


Figure 2. Methods used to prepare specimens for T-lymphocyte immunophenotyping, reported by participant laboratories to CDC for the September 1996 shipment.


Figure 3. Methods used to fix specimens for T-lymphocyte immunophenotyping, reported by participant laboratories to CDC for the September 1996 shipment.


Figure 4. Types of flow cytometers used for T-lymphocyte immunophenotyping, reported by participant laboratories to CDC for the September 1996 shipment.


CDC Model Performance Evaluation Program T-Lymphocyte Immunophenotyping

Table 1. Frequency of 2-c olor laboratory results for the September 1996 ship ment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC Donor Number -

\begin{tabular}{|c|c|c|c|c|c|c|c|c|c|c|c|c|}
\hline Cell Marker \& HIV Status \& \& \& \& \& \& \& \& \& \& \& \\
\hline opulation) \& 1 \& H \& 2 \& M \& 3 \& H \& 4 \& H \& 5 \& H \& 6 \& H \\
\hline \& Range \& No. \({ }^{\text {a }}\) \& Range \& No. \& Range \& No. \& Range \& No. \& Range \& No. \& Range \& No. \\
\hline CD45+ \& \[
\begin{aligned}
\& >100 \\
86 \& -100 \\
\& <86
\end{aligned}
\] \& \[
\begin{gathered}
0 \\
24 \\
0
\end{gathered}
\] \& \[
\begin{aligned}
\&>100 \\
\& 92-100 \\
\&<92 \\
\& \hline
\end{aligned}
\] \& \[
\begin{gathered}
0 \\
24 \\
0 \\
\hline
\end{gathered}
\] \& \[
\begin{array}{r}
>99 \\
94-99 \\
<94
\end{array}
\] \& \[
\begin{gathered}
0 \\
18 \\
4 \\
\hline
\end{gathered}
\] \& \[
\begin{array}{r}
>99 \\
94-99 \\
<94 \\
\hline
\end{array}
\] \& \[
\begin{gathered}
0 \\
18 \\
18 \\
0 \\
\hline
\end{gathered}
\] \& \[
\begin{aligned}
\&>100 \\
\& 92-100 \\
\&<92 \\
\& \hline
\end{aligned}
\] \& \[
\begin{gathered}
0 \\
24 \\
0 \\
\hline
\end{gathered}
\] \& \[
\begin{aligned}
\& >99 \\
93 \& -99 \\
\& <93
\end{aligned}
\] \& \begin{tabular}{c}
5 \\
21 \\
0 \\
\hline
\end{tabular} \\
\hline CD14+ \& \(\begin{aligned} \& >1 \\ 0 \& -1 \\ \& <0\end{aligned}\) \& \[
\begin{gathered}
0 \\
24 \\
0 \\
\hline
\end{gathered}
\] \& \(\begin{aligned} \& >1 \\ 0 \& -1 \\ \& <0\end{aligned}\) \& \begin{tabular}{c}
0 \\
24 \\
0 \\
\hline
\end{tabular} \& \(\begin{aligned} \&>0 \\ \& 0-0 \\ \&<0\end{aligned}\) \& \[
\begin{gathered}
2 \\
18 \\
0 \\
\hline
\end{gathered}
\] \& \(\begin{aligned} \&>2 \\ \& 0-2 \\ \&<0\end{aligned}\) \& 0
18
0 \& \(\begin{aligned} \&>1 \\ \& 0-1 \\ \&<\end{aligned}\) \& \begin{tabular}{c}
0 \\
24 \\
0 \\
\hline
\end{tabular} \& \(\begin{aligned} \&>2 \\ \& 0-2 \\ \&<0\end{aligned}\) \& \begin{tabular}{c}
0 \\
22 \\
0 \\
\hline
\end{tabular} \\
\hline CD3+CD4+ \& \[
\begin{aligned}
\&>53 \\
\& 39-53 \\
\&<39 \\
\& \hline
\end{aligned}
\] \& \[
\begin{gathered}
0 \\
24 \\
0 \\
\hline
\end{gathered}
\] \& \(\begin{aligned} \&>37 \\ \& 32-37 \\ \&<\end{aligned}\) \& \[
\begin{gathered}
0 \\
20 \\
0 \\
\hline
\end{gathered}
\] \& \(\begin{aligned} \&>34 \\ \& 32-34 \\ \&<\end{aligned}\) \& \[
\begin{aligned}
\& 2 \\
\& 9 \\
\& 5 \\
\& \hline
\end{aligned}
\] \& \(>\)
\(27-32\)
-32
\(<\) \& \[
\begin{gathered}
0 \\
16 \\
0 \\
\hline
\end{gathered}
\] \& \[
\begin{array}{r}
>49 \\
37-49 \\
<37 \\
\hline
\end{array}
\] \& \[
\begin{gathered}
c_{0} \\
22 \\
0 \\
\hline
\end{gathered}
\] \& \(\begin{aligned} \&>51 \\ \& 46-51 \\ \&<46\end{aligned}\) \& \begin{tabular}{c}
3 \\
18 \\
1 \\
\hline
\end{tabular} \\
\hline CD3+CD8+ \& \[
\begin{aligned}
\&>49 \\
\& 38-49 \\
\&<38 \\
\& \hline
\end{aligned}
\] \& \[
\begin{gathered}
0 \\
23 \\
1
\end{gathered}
\] \& \(\begin{aligned} \&>47 \\ \& 40-47 \\ \&<40\end{aligned}\) \& \[
\begin{gathered}
0 \\
20 \\
0 \\
\hline
\end{gathered}
\] \& \(\begin{aligned} \&>44 \\ \& 36-44 \\ \&<36\end{aligned}\) \& \[
\begin{array}{|c|}
\hline 3 \\
12 \\
1 \\
\hline
\end{array}
\] \& \(\begin{aligned} \& \\ \&>>53 \\ \& 46-53 \\ \&<46\end{aligned}\) \& \[
\begin{gathered}
0 \\
15 \\
1
\end{gathered}
\] \& \(>\)
\(36-45\)

$<$ \& $$
\begin{gathered}
c_{0} \\
20 \\
2
\end{gathered}
$$ \& $\begin{aligned} &>43 \\ & 35-43 \\ &<\end{aligned}$ \& $\begin{array}{r}1 \\ 21 \\ 0 \\ \hline\end{array}$ <br>

\hline CD3-CD19+ \& $\begin{aligned} &>8 \\ & 4-8 \\ &<4\end{aligned}$ \& \[
$$
\begin{gathered}
0 \\
14 \\
0 \\
\hline
\end{gathered}
$$

\] \& $\begin{aligned} &>15 \\ & 10-15 \\ &<\end{aligned}$ \& \[

$$
\begin{gathered}
0 \\
16 \\
0 \\
\hline
\end{gathered}
$$

\] \& $\begin{aligned} & >20 \\ 14 & -20 \\ & <14\end{aligned}$ \& \[

$$
\begin{gathered}
0 \\
14 \\
0 \\
\hline
\end{gathered}
$$

\] \& |  | $>20$ |
| ---: | :--- |
| 14 | -20 |
|  | $<14$ | \& | 0 |
| :---: |
| 14 |
| 0 | \& $>8$

$4-8$

$<4$ \& \[
$$
\begin{gathered}
\hline 0 \\
14 \\
0 \\
\hline
\end{gathered}
$$

\] \& $>$ \& | 0 |
| :---: |
| 16 |
| 0 | <br>

\hline CD3-(CD56
$\& C D 16)+$ \& $>$
$1-3$
-3

$<1$ \& $$
\begin{aligned}
& 0 \\
& 8 \\
& 0
\end{aligned}
$$ \& $>8$

$4-8$

$<4$ \& | 0 |
| :---: |
| 14 |
| 0 | \& $>9$

$6-9$

$<6$ \& | 2 |
| :--- |
| 6 |
| 2 | \& $>5$

$1-5$

$<1$ \& | 0 |
| :--- |
| 8 |
| 0 | \& $>7$

$5-7$
$<5$ \& 0
14
0 \& $>5$
$3-5$
$<3$ \& 0
8
0 <br>

\hline CD3+Average \& $$
\begin{array}{r}
>95 \\
88-95 \\
<88 \\
\hline
\end{array}
$$ \& \[

$$
\begin{gathered}
0 \\
22 \\
0
\end{gathered}
$$

\] \& \[

$$
\begin{array}{r}
>80 \\
74-80 \\
\\
<74 \\
\hline \hline
\end{array}
$$

\] \& \[

$$
\begin{gathered}
0 \\
18 \\
0 \\
\hline
\end{gathered}
$$

\] \& \[

$$
\begin{array}{r}
>74 \\
67-74 \\
\quad<67 \\
\hline \hline
\end{array}
$$

\] \& | 3 |
| :--- |
| 8 |
| 1 | \& \[

$$
\begin{array}{r}
>84 \\
78-84 \\
<78 \\
\hline \hline
\end{array}
$$

\] \& \[

$$
\begin{gathered}
0 \\
14 \\
0 \\
\hline
\end{gathered}
$$

\] \& \[

$$
\begin{array}{r}
>91 \\
86-91 \\
\\
<86 \\
\hline
\end{array}
$$

\] \& \[

$$
\begin{gathered}
0 \\
20 \\
20 \\
2
\end{gathered}
$$

\] \& \[

$$
\begin{array}{r}
>91 \\
88-91 \\
<88 \\
\hline \hline
\end{array}
$$

\] \& | 4 |
| :---: |
| 18 |
| 0 | <br>

\hline
\end{tabular}

*The $90 \%$ reference ranges were determined from results provided by partic ipant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ )

[^0]Table 1. Frequency of 2-color laboratory results for the September 1996 ship ment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC Donor Number -

| Cell Marker HIV Status** |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| n) | 7 - | M | 8 - | L | 9 | L | 10 | L | 11 - | L | 12 - | N |
|  | Range | No. ${ }^{\text {a }}$ | Range | No. | Range | No. | Range | No. | Range | No. | Range | No. |
| CD45+ | $\begin{aligned} & >100 \\ 90 & -100 \\ & <90\end{aligned}$ | $\begin{gathered} 0 \\ 26 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >100 \\ 90 & -100 \\ & <90\end{aligned}$ | $\begin{gathered} 0 \\ 18 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} &>100 \\ & 88-100 \\ &<88\end{aligned}$ | $\begin{gathered} 0 \\ 23 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>99 \\ & 92-99 \\ &<92\end{aligned}$ | $\begin{array}{c\|} \hline 3 \\ 21 \\ 1 \\ \hline \end{array}$ | $\begin{aligned} & >100 \\ 94 & -100 \\ & <94\end{aligned}$ | $\begin{gathered} 0 \\ 13 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>100 \\ & 90-100 \\ &<90 \\ & \hline \end{aligned}$ | 0 <br> 45 <br> 1 |
| CD14+ | $\begin{aligned} & \\ &> \\ & 0-1 \\ &<0\end{aligned}$ | $\begin{gathered} 2 \\ 24 \\ 0 \end{gathered}$ | $\begin{aligned} &>1 \\ & 0-1 \\ &<0\end{aligned}$ | $\begin{gathered} 1 \\ 18 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>1 \\ & 0-1 \\ &<0\end{aligned}$ | 0 <br> 23 <br> 0 | $\begin{aligned} &>1 \\ & 0-1 \\ &<0\end{aligned}$ | $\begin{gathered} 2 \\ 20 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>1 \\ & 0-1 \\ &<0\end{aligned}$ | $\begin{gathered} 1 \\ 12 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>1 \\ & 0-1 \\ &<0\end{aligned}$ | 1 <br> 42 <br> 0 |
| CD3+CD4+ |  $>48$ <br> 38 -48 <br> $<$  | $\begin{gathered} 0 \\ 24 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>22 \\ & 15-22 \\ &<\end{aligned}$ | 0 <br> 19 <br> 0 | $>$ $1-3$ -3 $<1$ | 1 <br> 19 <br> 0 | $\begin{aligned} & \\ & \\ & 10-14 \\ & \\ &<10\end{aligned}$ | 2 <br> 17 <br> 0 | $\begin{aligned} &>16 \\ & 10-16 \\ &<10\end{aligned}$ | 1 <br> 11 <br> 0 | $\begin{aligned} &>40 \\ & 29-40 \\ &<\end{aligned}$ | 0 <br> 38 <br> 1 |
| CD3+CD8+ | $\begin{aligned} &>50 \\ & 44-50 \\ &<\end{aligned}$ | $\begin{gathered} 0 \\ 21 \\ 3 \\ \hline \end{gathered}$ | $\begin{aligned} &>52 \\ & 40-52 \\ &<\end{aligned}$ | $\begin{gathered} 0 \\ 19 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} \\ >42 \\ 34-42 \\ <34 \\ \hline\end{array}$ | $\begin{gathered} 0 \\ 19 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} &>65 \\ & 57-65 \\ &<57\end{aligned}$ | $\begin{gathered} 1 \\ 17 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} &> \\ & 71 \\ & 71-75 \\ &<71\end{aligned}$ | $\begin{aligned} & 1 \\ & 9 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} &>29 \\ & 21-29 \\ &<21\end{aligned}$ | 1 <br> 36 <br> 2 |
| CD3-CD19+ | $\begin{aligned} &>6 \\ & 2-6 \\ &<2\end{aligned}$ | $\begin{gathered} 0 \\ 24 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >13 \\ 6 & -13 \\ & <6\end{aligned}$ | $\begin{gathered} 0 \\ 13 \\ 0 \\ \hline \end{gathered}$ | $>$ $32-44$ $<$ | 1 <br> 14 <br> 0 | $\begin{aligned} & >16 \\ 9 & -16 \\ & <9\end{aligned}$ | 1 <br> 13 <br> 1 <br> 1 | $\begin{aligned} &>8 \\ & 2-8 \\ &<2\end{aligned}$ | 0 <br> 12 <br> 0 | $\begin{aligned} &>24 \\ & 15-24 \\ &<\end{aligned}$ | 2 <br> 25 <br> 2 |
| CD3-(CD56 \& CD16)+ | $\begin{aligned} &>4 \\ & 2-4 \\ &<2\end{aligned}$ | $\begin{gathered} 0 \\ 16 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>22 \\ & 14-22 \\ &<14\end{aligned}$ | 0 <br> 8 <br> 0 | $\begin{aligned} & >15 \\ 9 & -15 \\ & <9\end{aligned}$ | 0 <br> 13 <br> 1 | $\begin{aligned} & >13 \\ 8 & -13 \\ & <8\end{aligned}$ |  | $\begin{aligned} &>3 \\ & 2-3 \\ &<2\end{aligned}$ | 0 <br> 8 <br> 0 | $\begin{aligned} &>11 \\ & 8-11 \\ &<8 \\ & \hline \end{aligned}$ | 2 <br> 14 <br> 1 |
| CD3+Average | $\begin{array}{r}>93 \\ 86-93 \\ <86 \\ \hline\end{array}$ | 0 15 1 | $>$ 60 -71 $<$ | 0 <br> 16 <br> 1 | > $\quad \begin{array}{r} \\ 44 \\ -53 \\ <44\end{array}$ | 0 <br> 18 <br> 2 | $>76$ $70-76$ $<70$ | 2 15 0 | $\begin{aligned} &>93 \\ & 88-93 \\ &<88\end{aligned}$ | 0 7 1 | $\begin{array}{rl} & > \\ 67 \\ 67 & 77 \\ <67\end{array}$ | 0 <br> 32 <br> 3 |

*The $90 \%$ reference ranges were determined from results provided by partic ipant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
** HIV status: $N=$ Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ ) ${ }^{\Delta}=$ frequency of laboratories

Table 1. Frequency of 2-color laboratory results for the September 1996 ship ment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC Donor Number -

| Cell Marker HIV Status** |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| opulation) | 13 | N | 14 - | N | 15 | N | 16 | H | 17 | H | 18 | H |
|  | Range | No. ${ }^{\text {a }}$ | Range | No. | Range | No. | Range | No. | Range | No. | Range | No. |
| CD45+ | $\begin{aligned} & >100 \\ 92 & -100 \\ & <92 \end{aligned}$ | $\begin{gathered} 0 \\ 44 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} & >100 \\ 92 & -100 \\ & <92 \end{aligned}$ | $\begin{gathered} 0 \\ 37 \\ 1 \end{gathered}$ | $\begin{array}{r} >99 \\ 89-99 \\ <89 \end{array}$ | $\begin{gathered} 2 \\ 33 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} & >100 \\ 93 & -100 \\ & <93 \end{aligned}$ | $\begin{gathered} 0 \\ 16 \\ 0 \end{gathered}$ | $\begin{aligned} & >100 \\ 92 & -100 \\ & <92 \end{aligned}$ | $\begin{gathered} 0 \\ 24 \\ 0 \end{gathered}$ | $\begin{aligned} & >99 \\ 95 & -99 \\ & <95\end{aligned}$ | 0 17 1 |
| CD14+ | $\begin{aligned} &>2 \\ & 0-2 \\ &<0\end{aligned}$ | $\begin{gathered} 1 \\ 44 \\ 0 \end{gathered}$ | $\begin{aligned} &>1 \\ & 0-1 \\ &<0\end{aligned}$ | $\begin{gathered} 1 \\ 35 \\ 0 \end{gathered}$ | $\begin{aligned} &>2 \\ & 0-2 \\ &<0\end{aligned}$ | $\begin{gathered} 2 \\ 33 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>0 \\ & 0-0 \\ &<0\end{aligned}$ | $\begin{gathered} 3 \\ 11 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>1 \\ & 0-1 \\ &<0\end{aligned}$ | $\begin{gathered} 2 \\ 22 \\ 0 \end{gathered}$ | $\begin{aligned} & >1 \\ 0 & -1 \\ & <0\end{aligned}$ | 0 <br> 16 <br> 0 |
| CD3+CD4 | $\begin{aligned} &>53 \\ & 46-53 \\ &<46 \\ & \hline \end{aligned}$ | $\begin{gathered} 1 \\ 39 \\ 1 \end{gathered}$ | $\begin{aligned} & >67 \\ 60 & -67 \\ & <60 \end{aligned}$ | $\begin{gathered} 2 \\ 29 \\ 2 \end{gathered}$ | $\begin{array}{r} >42 \\ 33-42 \\ <33 \end{array}$ | $\begin{gathered} 0 \\ 30 \\ 0 \end{gathered}$ | $\begin{aligned} & >41 \\ 32 & -41 \\ & <32 \end{aligned}$ | $\begin{gathered} 0 \\ 12 \\ 0 \end{gathered}$ | $\begin{array}{r} >33 \\ 27-33 \\ <27 \end{array}$ | $\begin{gathered} 0 \\ 24 \\ 0 \end{gathered}$ | $\begin{aligned} &>52 \\ & 46-52 \\ &<46\end{aligned}$ | 0 17 1 |
| CD3+CD8+ | $\begin{aligned} &>27 \\ & 22-27 \\ &<22 \\ & \hline \end{aligned}$ | $\begin{gathered} 1 \\ 38 \\ 2 \\ \hline \end{gathered}$ | $\begin{aligned} &>21 \\ & 16-21 \\ &<16 \\ & \hline \end{aligned}$ | $\begin{gathered} 1 \\ 32 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>31 \\ & 22-31 \\ &<22 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 30 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>50 \\ & 40-50 \\ &<40 \\ & \hline \end{aligned}$ | $\begin{gathered} 2 \\ 10 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>60 \\ & 48-60 \\ &<48 \\ & \hline \end{aligned}$ | $\begin{gathered} 1 \\ 23 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>22 \\ & 13-22 \\ &<\end{aligned}$ | 0 <br> 20 <br> 0 |
| CD3-CD19+ | $\begin{aligned} & >13 \\ 9 & -13 \\ & <9\end{aligned}$ | $\begin{gathered} 1 \\ 27 \\ 1 \end{gathered}$ | $\begin{aligned} &>8 \\ & 6-8 \\ &<6\end{aligned}$ | $\begin{gathered} 1 \\ 26 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} & >20 \\ 15 & -20 \\ & <15 \end{aligned}$ | $\begin{gathered} 0 \\ 25 \\ 1 \end{gathered}$ | $\begin{aligned} &>9 \\ & 6-9 \\ &<6\end{aligned}$ | $\begin{gathered} 0 \\ 14 \\ 0 \end{gathered}$ | $\begin{aligned} & >10 \\ 7 & -10 \\ & <7 \end{aligned}$ | $\begin{gathered} 0 \\ 20 \\ 20 \\ 0 \end{gathered}$ | $\begin{array}{r} >22 \\ 17-22 \\ <17 \end{array}$ | 0 18 0 |
| CD3-(CD56 $\&$ CD16)+ | $\begin{array}{r} >17 \\ 11-17 \\ <11 \\ \hline \end{array}$ | $\begin{gathered} 1 \\ 20 \\ 1 \\ \hline \end{gathered}$ | $\begin{array}{r} >8 \\ 5-8 \\ <5 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 19 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>16 \\ & 11-16 \\ &<11 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 17 \\ 3 \end{gathered}$ | $\begin{array}{r} >6 \\ 5-6 \\ <5 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 10 \\ 2 \\ \hline \end{gathered}$ | $\begin{array}{r} >3 \\ 2-3 \\ <2 \\ \hline \end{array}$ | $\begin{array}{c\|c} 0 \\ 16 \\ 0 \end{array}$ | $\begin{aligned} &>12 \\ & 10-12 \\ &< 10 \\ & \hline \end{aligned}$ | 0 <br> 6 <br> 0 |
| CD3+Average | $\begin{aligned} &> \\ & 73 \\ & 73-78 \\ &< 73\end{aligned}$ | $\begin{gathered} 3 \\ 33 \\ 2 \\ \hline \hline \end{gathered}$ | $\begin{aligned} &>89 \\ & 80-89 \\ &<80\end{aligned}$ | $\begin{gathered} 1 \\ 27 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &> \\ & 63 \\ & 63-71 \\ &<63\end{aligned}$ | 0 25 0 | $\begin{array}{r} >89 \\ 84-89 \\ \\ <84 \\ \hline \hline \end{array}$ | 0 12 2 | $\begin{aligned} &>91 \\ & 84-91 \\ &<84\end{aligned}$ | 0 20 0 |  $>$ <br> 65  <br> 65  <br>   <br> $<$ 71 | 0 16 0 |

*The $90 \%$ reference ranges were determined from results provided by partic ipant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ ) ${ }^{\Delta}=$ frequenc $y$ of laboratories

Table 1. Frequency of 2-c olor laboratory results for the September 1996 ship ment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC Donor Number -

| Cell Marker |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 19 | H | 20 | H | 21 | H | 22 | H | 23 | L | 24 | L |
|  | Range | Nos | Range | No. | Range | No. | Range | No. | Range | No. | Range | No. |
| CD45+ | $\begin{array}{r} >99 \\ 95-99 \\ \\ <95 \end{array}$ | $\begin{gathered} 6 \\ 16 \\ 0 \end{gathered}$ | $\begin{aligned} & >100 \\ 93 & -100 \\ & <93 \end{aligned}$ | $\begin{gathered} 0 \\ 32 \\ 0 \end{gathered}$ | $\begin{aligned} & >100 \\ 97 & -100 \\ & <97 \end{aligned}$ | $\begin{gathered} 2 \\ 20 \\ 2 \\ \hline \end{gathered}$ | $\begin{aligned} & >100 \\ 95 & -100 \\ & <95 \end{aligned}$ | $\begin{gathered} 0 \\ 0 \\ 22 \\ 2 \end{gathered}$ | $\begin{aligned} & >100 \\ 93 & -100 \\ & <93 \end{aligned}$ | $\begin{gathered} 0 \\ 19 \\ 0 \end{gathered}$ | $\begin{aligned} & >100 \\ 94 & -100 \\ & <94 \end{aligned}$ | 0 27 1 |
| CD14+ | $\begin{aligned} &>1 \\ & 0-1 \\ &<0\end{aligned}$ | $\begin{gathered} 0 \\ 20 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>1 \\ & 0-1 \\ &<0\end{aligned}$ | $\begin{gathered} 0 \\ 32 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>1 \\ & 0-1 \\ &<0\end{aligned}$ | $\begin{gathered} 0 \\ 22 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >1 \\ 0 & -1 \\ & <0\end{aligned}$ | $\begin{gathered} 2 \\ 22 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >2 \\ 0-2 \\ <0 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 17 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >1 \\ 0-1 \\ <0 \end{array}$ | 1 <br> 27 <br> 0 |
| CD3+CD4+ | $\begin{aligned} &> \\ & 39 \\ & 33-39 \\ &<\end{aligned}$ | $\begin{gathered} 3 \\ 17 \\ 0 \end{gathered}$ | $\begin{array}{r} >46 \\ 33-46 \\ <33 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 30 \\ 0 \end{gathered}$ | $\begin{aligned} &>53 \\ & 45-53 \\ &<45\end{aligned}$ | $\begin{gathered} 0 \\ 22 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>36 \\ & 25-36 \\ &<25\end{aligned}$ | $\begin{gathered} 1 \\ 23 \\ 0 \end{gathered}$ | $\begin{aligned} &>8 \\ & 6-8 \\ &<6\end{aligned}$ | $\begin{gathered} 0 \\ 16 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>8 \\ & 7-8 \\ &<\end{aligned}$ | 2 25 0 |
| CD3+CD8+ | $\begin{aligned} &>38 \\ & 34-38 \\ &<34\end{aligned}$ | $\begin{gathered} 0 \\ 18 \\ 2 \\ \hline \end{gathered}$ | $\begin{array}{r} >41 \\ 33-41 \\ <33 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 30 \\ 0 \end{gathered}$ | $\begin{array}{r} >46 \\ 35-46 \\ <35 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 22 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >48 \\ 40-48 \\ <40 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 20 \\ 4 \\ \hline \end{gathered}$ | $\begin{array}{r} >85 \\ 77-85 \\ <77 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 15 \\ 15 \\ 1 \end{gathered}$ | $\begin{array}{r} >67 \\ 57-67 \\ \\ <57 \end{array}$ | 0 <br> 25 <br> 2 |
| CD3-CD19+ | $\begin{aligned} & \\ & \\ & 11>16 \\ &-16 \\ &<11\end{aligned}$ | $\begin{gathered} 0 \\ 19 \\ 1 \end{gathered}$ | $\begin{aligned} & >14 \\ 9 & -14 \\ & <9\end{aligned}$ | $\begin{gathered} 0 \\ 22 \\ 2 \\ \hline \end{gathered}$ | $\begin{aligned} & >10 \\ 6 & -10 \\ & <6 \end{aligned}$ | $\begin{gathered} 1 \\ 19 \\ 0 \end{gathered}$ | $\begin{aligned} & >16 \\ 9 & -16 \\ & <9\end{aligned}$ | $\begin{gathered} 0 \\ 16 \\ 0 \end{gathered}$ | $\begin{aligned} &>6 \\ & 4-6 \\ &<4\end{aligned}$ | $\begin{gathered} 0 \\ 17 \\ 17 \\ 0 \end{gathered}$ | $\begin{array}{r} >25 \\ 15-25 \\ <15 \end{array}$ | 0 21 1 |
| CD3-(CD56 \& CD16)+ | $\begin{aligned} & >14 \\ 7 & -14 \\ & <7 \end{aligned}$ | $\begin{gathered} 0 \\ 16 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >11 \\ 6 & -11 \\ & <6 \end{aligned}$ | $\begin{gathered} 0 \\ 19 \\ 1 \\ \hline \end{gathered}$ | $\begin{array}{r} >7 \\ 3-7 \\ <3 \end{array}$ | $\begin{gathered} 0 \\ 10 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>11 \\ & 7-11 \\ &<7 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 13 \\ 13 \\ 1 \end{gathered}$ | $\begin{array}{r} >6 \\ 2-6 \\ \\ <2 \end{array}$ | $\begin{gathered} 0 \\ 14 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>13 \\ & 7-13 \\ &<7 \\ & \hline \end{aligned}$ | 0 <br> 18 <br> 0 |
| CD3+Average | $\begin{aligned} &>76 \\ & 69-76 \\ &<69 \\ & \hline \end{aligned}$ | $\begin{gathered} 1 \\ 19 \\ 0 \\ \hline \hline \end{gathered}$ | $\begin{array}{r} >84 \\ 74-84 \\ <74 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 22 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >92 \\ 86-92 \\ \\ <86 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 18 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >83 \\ 73-83 \\ <73 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 18 \\ 18 \\ 0 \end{gathered}$ | $\begin{array}{r} >92 \\ 86-92 \\ <86 \\ \hline \end{array}$ | $\left.\begin{gathered} 0 \\ 16 \\ 1 \end{gathered} \right\rvert\,$ | $\begin{array}{r} >75 \\ 64-75 \\ \\ <64 \end{array}$ | 0 21 0 |

*The $90 \%$ reference ranges were determined from results provided by partic ipant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
** HIV status: $N=$ Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ ) ${ }^{\wedge}=$ frequency of laboratories

Table 1. Frequency of 2-c olor laboratory results for the September 1996 ship ment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC Donor Number -

| Cell Marker (Population) | HIV Status** |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 25 | M | 26 | L | 27 | N | 28 | N | 29 | N | 30 | N |
|  | Range | No. ${ }^{\text {a }}$ | Range | No. | Range | No. | Range | No. | Range | No. | Range | No. |
| CD45+ | $\begin{aligned} & >100 \\ 94 & -100 \\ & <94 \end{aligned}$ | $\begin{gathered} 0 \\ 20 \\ 1 \end{gathered}$ | $\begin{aligned} & >100 \\ 85 & -100 \\ & <85 \end{aligned}$ | $\begin{gathered} 0 \\ 11 \\ 1 \end{gathered}$ | $\begin{aligned} & >100 \\ 95 & -100 \\ & <95 \end{aligned}$ | $\begin{gathered} 1 \\ 37 \\ 2 \end{gathered}$ | $\begin{aligned} & >100 \\ 93 & -100 \\ & <93 \end{aligned}$ | $\begin{gathered} 0 \\ 46 \\ 1 \end{gathered}$ | $\begin{aligned} & >100 \\ 89 & -100 \\ & <89 \end{aligned}$ | $\begin{gathered} 0 \\ 38 \\ 2 \end{gathered}$ | $\begin{aligned} & >100 \\ 94 & -100 \\ & <94 \end{aligned}$ | 1 28 4 |
| CD14+ | $\begin{array}{r} >1 \\ 0-1 \\ \\ < \end{array}$ | $\begin{gathered} 0 \\ 19 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >1 \\ 0-1 \\ <0 \end{array}$ | $\begin{gathered} 1 \\ 11 \\ 0 \end{gathered}$ | $\begin{array}{r} >1 \\ 0-1 \\ <0 \end{array}$ | $\begin{gathered} 0 \\ 36 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >1 \\ 0-1 \\ \\ < \end{array}$ | $\begin{gathered} 1 \\ 44 \\ 0 \end{gathered}$ | $\begin{array}{r} >1 \\ 0-1 \\ <0 \end{array}$ | $\begin{gathered} 2 \\ 38 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >2 \\ 0-2 \\ \\ <0 \end{array}$ | 1 30 0 |
| CD3+CD4+ | $\begin{aligned} & >14 \\ 9 & -14 \\ & <9 \end{aligned}$ | $\begin{gathered} 0 \\ 20 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >24 \\ 18-24 \\ <18 \end{array}$ | $\begin{gathered} 1 \\ 11 \\ 0 \end{gathered}$ | $\begin{array}{r} >55 \\ 49-55 \\ <49 \\ \hline \end{array}$ | $\begin{gathered} 1 \\ 32 \\ 3 \end{gathered}$ | $\begin{array}{r} >45 \\ 37-45 \\ <37 \end{array}$ | $\begin{gathered} 0 \\ 43 \\ 0 \end{gathered}$ | $\begin{aligned} &>62 \\ & 55-62 \\ &<55 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 36 \\ 2 \end{gathered}$ | $\begin{aligned} & >45 \\ 40 & -45 \\ & <40 \end{aligned}$ | 2 26 4 |
| CD3+CD8+ | $\begin{aligned} &>76 \\ & 67-76 \\ &<67 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 19 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} &>56 \\ & 46-56 \\ &<46 \\ & \hline \end{aligned}$ | $\begin{aligned} & 1 \\ & 9 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{aligned} &>33 \\ & 26-33 \\ &<26 \\ & \hline \end{aligned}$ | $\begin{gathered} 1 \\ 34 \\ 2 \\ \hline \end{gathered}$ | $\begin{array}{r} >38 \\ 32-38 \\ \\ <32 \end{array}$ | $\begin{gathered} 0 \\ 41 \\ 2 \\ \hline \end{gathered}$ | $\begin{aligned} &>28 \\ & 22-28 \\ &<22 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 36 \\ 3 \\ \hline \end{gathered}$ | $\begin{aligned} &>26 \\ & 22-26 \\ &<22 \\ & \hline \end{aligned}$ | 1 <br> 28 <br> 4 |
| CD3-CD19+ | $\begin{aligned} & >14 \\ 8 & -14 \\ & <8 \end{aligned}$ | $\begin{gathered} 0 \\ 19 \\ 0 \end{gathered}$ | $\begin{array}{r} >23 \\ 11-23 \\ \\ <11 \end{array}$ | $\begin{aligned} & 0 \\ & 8 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{array}{r} >8 \\ 5-8 \\ <5 \end{array}$ | $\begin{gathered} 0 \\ 36 \\ 0 \end{gathered}$ | $\begin{aligned} & >13 \\ 8 & -13 \\ & <8 \end{aligned}$ | $\begin{gathered} 0 \\ 38 \\ 1 \end{gathered}$ | $\begin{aligned} & >11 \\ 7 & -11 \\ & <7 \end{aligned}$ | $\begin{gathered} 0 \\ 30 \\ 30 \\ 0 \end{gathered}$ | $\begin{aligned} & >22 \\ 15 & -22 \\ & <15 \end{aligned}$ | 0 26 1 |
| CD3-(CD56 \& CD16)+ | $\begin{array}{r} >4 \\ 2-4 \\ <2 \\ \hline \end{array}$ | $\begin{aligned} & 1 \\ & 7 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{array}{r} >7 \\ 3-7 \\ <3 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 6 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} &>10 \\ & 7-10 \\ &<7 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 20 \\ 2 \\ \hline \end{gathered}$ | $\begin{aligned} & >11 \\ 7 & -11 \\ & <7 \end{aligned}$ | $\begin{gathered} 1 \\ 31 \\ 31 \\ 0 \end{gathered}$ | $\begin{array}{r} >7 \\ 5-7 \\ <5 \\ \hline \end{array}$ | $\begin{gathered} 1 \\ 23 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} &>20 \\ & 11-20 \\ &<11 \\ & \hline \end{aligned}$ | 0 15 0 |
| CD3+Average | $\begin{aligned} &>90 \\ & 80-90 \\ &<80 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 17 \\ 0 \end{gathered}$ | $\begin{aligned} &>81 \\ & 70-81 \\ &<70 \\ & \hline \end{aligned}$ | $\begin{aligned} & 2 \\ & 6 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} & >87 \\ 83 & -87 \\ & <83 \end{aligned}$ | $\begin{gathered} 1 \\ 31 \\ 2 \\ \hline \end{gathered}$ | $\begin{array}{r} >85 \\ 74-85 \\ \\ <74 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 37 \\ 1 \end{gathered}$ | $\begin{array}{r}  \\ >88 \\ 81 \end{array} \quad 88$ | $\begin{gathered} 1 \\ 26 \\ 26 \\ 3 \end{gathered}$ | $\begin{aligned} &>70 \\ & 63-70 \\ &<63 \\ & \hline \hline \end{aligned}$ | 0 25 1 |

*The $90 \%$ reference ranges were determined from results provided by partic ipant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
** HIV status: $N=$ Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ ) ${ }^{\wedge}=$ frequency of laboratories

Table 1. Frequency of 2-color laboratory results for the September 1996 ship ment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC Donor Number -

| Cell Marker | HIV Status |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| opulation) | 31 - | H | 32 | H | 33 | H | 34 | H | 35 | H | 36 | H |
|  | Range | No. ${ }^{\text {a }}$ | Range | No. | Range | No. | Range | No. | Range | No. | Range | No. |
| CD45+ | $\begin{aligned} & >100 \\ 96 & -100 \\ & <96 \end{aligned}$ | $\begin{gathered} 0 \\ 28 \\ 2 \end{gathered}$ | $\begin{array}{r} >99 \\ 92-99 \\ <92 \end{array}$ | $\begin{gathered} 6 \\ 19 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >99 \\ 93 & -99 \\ & <93 \end{aligned}$ | $\begin{gathered} 3 \\ 20 \\ 3 \end{gathered}$ | $\begin{aligned} & >100 \\ 95 & -100 \\ & <95 \end{aligned}$ | $\begin{gathered} 0 \\ 26 \\ 0 \end{gathered}$ | $\begin{aligned} & >100 \\ 98 & -100 \\ & <98 \end{aligned}$ | $\begin{array}{c\|\|} 0 \\ 19 \\ 1 \end{array}$ | $\begin{aligned} & >100 \\ 93 & -100 \\ & <93 \end{aligned}$ | 0 18 0 |
| CD14+ | $\begin{aligned} & >1 \\ 0 & -1 \\ & <0\end{aligned}$ | $\begin{gathered} 0 \\ 30 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>1 \\ & 0-1 \\ &<0\end{aligned}$ | $\begin{gathered} 1 \\ 20 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>2 \\ & 0-2 \\ &<0\end{aligned}$ | $\begin{gathered} 1 \\ 25 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>1 \\ & 0-1 \\ &<0\end{aligned}$ | $\begin{gathered} 2 \\ 22 \\ 0 \end{gathered}$ | $\begin{aligned} &>0 \\ & 0-0 \\ &<0\end{aligned}$ | $\begin{gathered} 2 \\ 18 \\ 18 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >1 \\ 0 & -1 \\ & <0\end{aligned}$ | 0 <br> 18 <br> 0 |
| CD3+CD4+ | $\begin{array}{r} >42 \\ 37-42 \\ <37 \end{array}$ | $\begin{gathered} 2 \\ 28 \\ 2 \\ \hline \end{gathered}$ | $\begin{aligned} &>32 \\ & 27-32 \\ &<27\end{aligned}$ | $\begin{gathered} 0 \\ 24 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} &>30 \\ & 27-30 \\ &<27\end{aligned}$ | $\begin{gathered} 1 \\ 17 \\ 2 \end{gathered}$ | $\begin{aligned} &>36 \\ & 32-36 \\ &<32\end{aligned}$ | $\begin{gathered} 0 \\ 26 \\ 0 \end{gathered}$ | $\begin{aligned} &>39 \\ & 24-39 \\ &<24\end{aligned}$ | $\begin{gathered} 0 \\ 22 \\ 0 \end{gathered}$ | $\begin{aligned} &>45 \\ & 32-45 \\ &<32 \\ & \hline \end{aligned}$ | 0 20 0 |
| CD3+CD8+ |  $>39$ <br> 35 -39 <br> $<$  | $\begin{gathered} 4 \\ 26 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>53 \\ & 47-53 \\ &<\end{aligned}$ | $\begin{gathered} 0 \\ 21 \\ 4 \\ \hline \end{gathered}$ | $\begin{aligned} &>52 \\ & 47-52 \\ &<47\end{aligned}$ | $\begin{gathered} 5 \\ 11 \\ 4 \\ \hline \end{gathered}$ | $\begin{aligned} &>58 \\ & 53-58 \\ &<53 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 24 \\ 2 \\ \hline \end{gathered}$ | $\begin{array}{r} >56 \\ 49-56 \\ <49 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 19 \\ 19 \\ 3 \\ \hline \end{gathered}$ | $\begin{aligned} & >52 \\ 39 & -52 \\ & <39\end{aligned}$ | 0 20 0 |
| CD3-CD19+ | $\begin{aligned} &>7 \\ & 4-7 \\ &<4\end{aligned}$ | $\begin{gathered} 0 \\ 18 \\ 0 \end{gathered}$ | $\begin{aligned} &>15 \\ & 10-15 \\ &<10\end{aligned}$ | $\begin{gathered} 0 \\ 19 \\ 0 \end{gathered}$ | $\begin{aligned} & \\ &> 15 \\ & 11-15 \\ &<11\end{aligned}$ | $\begin{gathered} 2 \\ 12 \\ 2 \end{gathered}$ | $\begin{aligned} &> 6 \\ & 2-6 \\ &<2\end{aligned}$ | $\begin{gathered} 2 \\ 18 \\ 18 \\ 0 \end{gathered}$ | $\begin{aligned} &>9 \\ & 2-9 \\ &<2\end{aligned}$ | $\begin{array}{c\|\|} \hline 0 \\ 16 \\ 0 \\ 0 \end{array}$ | $\begin{aligned} & >10 \\ 2 & -10 \\ & <2 \end{aligned}$ | 0 14 0 |
| CD3-(CD56 $\&$ CD16)+ | $\begin{aligned} &>18 \\ & 12-18 \\ &<12\end{aligned}$ | $\begin{gathered} 0 \\ 14 \\ 0 \\ \hline \end{gathered}$ | $>$ $1-8$ -8 $<1$ | $\begin{gathered} 0 \\ 15 \\ 0 \end{gathered}$ | $>5$ $3-5$ $<3$ | $\begin{gathered} 3 \\ 14 \\ 14 \\ \hline \end{gathered}$ | $>5$ $3-5$ $<3$ | $\begin{gathered} 0 \\ 10 \\ 0 \end{gathered}$ | $\begin{aligned} &>6 \\ & 3-6 \\ &<3\end{aligned}$ | $\begin{array}{c\|\|} 1 \\ 11 \\ 11 \\ 0 \end{array}$ | $\begin{aligned} &>9 \\ & 1-9 \\ &<1\end{aligned}$ | 0 <br> 12 <br> 0 |
| CD3+Average | $\begin{array}{r} >79 \\ 75-79 \\ <75 \\ \hline \end{array}$ | $\begin{gathered} 9 \\ 12 \\ 1 \\ \hline \hline \end{gathered}$ | $\begin{array}{r} >86 \\ 76-86 \\ \\ <76 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 23 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>83 \\ & 78-83 \\ &<78 \\ & \hline \end{aligned}$ | $\begin{gathered} 3 \\ 11 \\ 2 \\ \hline \end{gathered}$ | $\begin{aligned} &>93 \\ & 88-93 \\ &<88 \\ & \hline \end{aligned}$ | $\begin{gathered} c_{0} \\ 18 \\ 0 \\ \hline \end{gathered}$ | $\begin{array}{r} >93 \\ 85-93 \\ <85 \\ \hline \end{array}$ | $\begin{gathered} 0 \\ 17 \\ 17 \\ 3 \end{gathered}$ | $\begin{aligned} & >87 \\ 82 & -87 \\ & <82 \end{aligned}$ | 0 17 1 |

*The $90 \%$ reference ranges were determined from results provided by partic ipant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ ) ${ }^{\Delta}=$ frequency of laboratories

Table 1. Frequency of 2-c olor laboratory results for the September 1996 ship ment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC Donor Number -

| Cell |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Populatio | 37 - | H | 38 | L | 39 | L | 40 | L | 41 |  |
|  | Range | No. ${ }^{\wedge}$ | Range | No. | Range | No. | Range | No. | Range | No. |
| CD45+ | $\begin{aligned} & >100 \\ 87 & -100 \\ & <87\end{aligned}$ | $\begin{gathered} 0 \\ 22 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >100 \\ 93 & -100 \\ & <93 \end{aligned}$ | $\begin{gathered} 0 \\ 28 \\ 0 \end{gathered}$ | $\begin{aligned} & >100 \\ 91 & -100 \\ & <91\end{aligned}$ | $\begin{array}{\|c\|\|} \hline 0 \\ 21 \\ 0 \end{array}$ | $\begin{aligned} & >100 \\ 93 & -100 \\ & <93\end{aligned}$ | $\begin{gathered} 1 \\ 21 \\ 0 \end{gathered}$ | $\begin{aligned} & >99 \\ 95 & -99 \\ & <95\end{aligned}$ | 0 <br> 10 <br> 1 |
| CD14+ | $\begin{aligned} & >1 \\ 0 & -1 \\ & <0\end{aligned}$ | $\begin{gathered} 0 \\ 22 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>2 \\ & 0-2 \\ &<0\end{aligned}$ | 1 26 0 0 | $\begin{aligned} &>1 \\ & 0-1 \\ &<0\end{aligned}$ | $\begin{gathered} 0 \\ 19 \\ 0 \\ 0 \end{gathered}$ | $\begin{aligned} &>2 \\ & 0-2 \\ &<0\end{aligned}$ | $\begin{gathered} 1 \\ 21 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >1 \\ 0 & -1 \\ & <0\end{aligned}$ | 0 <br> 11 <br> 0 |
| CD3+CD4+ | $\begin{aligned} & \\ &> \\ & 31\end{aligned}$ | $\begin{gathered} 0 \\ 22 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >12 \\ 8 & -12 \\ & <8\end{aligned}$ | 0 <br> 29 <br> 0 | $\begin{aligned} &>6 \\ & 3-6 \\ &<\end{aligned}$ | $\begin{gathered} 0 \\ 22 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >12 \\ 9 & -12 \\ & <9\end{aligned}$ | $\begin{gathered} 0 \\ 20 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>18 \\ & 15-18 \\ &<\end{aligned}$ | 0 <br> 11 <br> 0 |
| CD3+CD8+ | $\begin{aligned} & \\ &>41 \\ & 31-41 \\ &< \\ &\end{aligned}$ | $\begin{gathered} 0 \\ 22 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & \\ &>64 \\ & 57-64 \\ &<57\end{aligned}$ | $\begin{gathered} 0 \\ 24 \\ 4 \\ \hline \end{gathered}$ | $\begin{aligned} & \\ &>82 \\ & 71-82 \\ &<71\end{aligned}$ | $\begin{gathered} 1 \\ 21 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & \\ &>68 \\ & 60-68 \\ &<60\end{aligned}$ | $\begin{gathered} 0 \\ 19 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} &>56 \\ & 51-56 \\ &<51\end{aligned}$ | 0 <br> 9 <br> 2 |
| CD3-CD19+ | $\begin{aligned} & \\ &>22 \\ & 10-22 \\ &<\end{aligned}$ | $\begin{gathered} 0 \\ 18 \\ 0 \end{gathered}$ | $\begin{aligned} &>5 \\ & 1-5 \\ &<\end{aligned}$ | 0 <br> 19 <br> 0 | $\begin{aligned} & \\ &> 6 \\ & 1-6 \\ &<1\end{aligned}$ | $\begin{array}{\|c\|\|} \hline 0 \\ 17 \\ 0 \\ \hline \end{array}$ | $\begin{aligned} & \\ &>17 \\ & 13-17 \\ &<\end{aligned}$ | 4 <br> 11 <br> 0 | $\begin{aligned} & >14 \\ 9 & -14 \\ & <9\end{aligned}$ | 0 <br> 9 <br> 0 |
| $\begin{gathered} \text { CD3-(CD56 } \\ \& \text { CD16)+ } \end{gathered}$ | $\begin{aligned} & >10 \\ 2 & -10 \\ & <2\end{aligned}$ | $\begin{gathered} 0 \\ 14 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>26 \\ & 20-26 \\ &<20\end{aligned}$ | 1 <br> 9 <br> 2 | $>$ | $\begin{array}{c\|\|} \hline 1 \\ 12 \\ 0 \\ \hline \end{array}$ | $>$ | 1 <br> 14 <br> 0 | $>$ $>$ $7-9$ $<7$ | 0 7 0 0 |
| CD3+ <br> Average | $\begin{aligned} & >80 \\ 69 & -80 \\ & <69\end{aligned}$ | $\begin{gathered} 0 \\ 22 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & > \\ & 76 \\ 69 & -76 \\ & <69\end{aligned}$ | 1 19 0 | $\begin{aligned} &>89 \\ & 78-89 \\ &<\end{aligned}$ | $\begin{gathered} 0 \\ 20 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>84 \\ & 71-84 \\ &<\end{aligned}$ | 0 16 1 | $\begin{aligned} &>81 \\ & 75-81 \\ &<\end{aligned}$ | 0 9 2 |

*The $90 \%$ reference ranges were determined from results provided by participant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic ienc y Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).

[^1]Table 1. Frequency of 2-c olor laboratory results for the September 1996 ship ment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC DonorNumber -

| Cell Marker HIV Status** |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (Populatio | $42-N$ |  | 43 |  | $44-N$ |  | 45 | N |
|  | Range No. | No. ${ }^{\text {A }}$ | Range | No. | Range | No. | Range | No. |
| CD45+ | $\begin{aligned} &>100 \\ & 93-100 \\ &<93 \\ & \hline \end{aligned}$ | $\begin{gathered} 1 \\ 48 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} &>100 \\ & 93-100 \\ &<93 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 50 \\ 1 \end{gathered}$ | $\begin{aligned} & >100 \\ 91 & -100 \\ & <91\end{aligned}$ | $\begin{gathered} 1 \\ 35 \\ 0 \end{gathered}$ | $\begin{aligned} &>100 \\ & 93-100 \\ &<93 \\ & \hline \end{aligned}$ | 0 <br> 29 <br> 1 |
| CD14+ | $\begin{aligned} & >1 \\ 0 & -1 \\ & <0\end{aligned}$ | 3 <br> 46 <br> 0 | $\begin{aligned} & >1 \\ 0 & -1 \\ & <0\end{aligned}$ | $\begin{gathered} 3 \\ 45 \\ 0 \end{gathered}$ | $\begin{aligned} & >1 \\ 0 & -1 \\ & <0\end{aligned}$ | 3 <br> 31 <br> 0 | $\begin{aligned} & >1 \\ 0 & -1 \\ & <0\end{aligned}$ | 1 <br> 29 <br> 0 |
| CD3+CD4+ | $\begin{aligned} &>57 \\ & 50-57 \\ &<50 \\ & \hline \end{aligned}$ | $\begin{gathered} 3 \\ 44 \\ 2 \\ \hline \end{gathered}$ | $\begin{aligned} &>63 \\ & 55-63 \\ &<55 \\ & \hline \end{aligned}$ | $\begin{gathered} 3 \\ 49 \\ 49 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} & \\ &>54 \\ & 47-54 \\ &<\end{aligned}$ | $\begin{gathered} 2 \\ 30 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} &>54 \\ & 49-54 \\ &<\end{aligned}$ | 3 <br> 27 <br> 2 |
| CD3+CD8+ | $\begin{aligned} &>28 \\ & 22-28 \\ &<22\end{aligned}$ | $\begin{gathered} 2 \\ 41 \\ 5 \\ \hline \end{gathered}$ | $\begin{aligned} & \\ &>24 \\ & 17-24 \\ &<\end{aligned}$ | $\begin{gathered} 2 \\ 47 \\ 3 \\ \hline \end{gathered}$ | $\begin{aligned} &>23 \\ & 18-23 \\ &<18\end{aligned}$ | $\begin{gathered} 0 \\ 30 \\ 3 \\ \hline \end{gathered}$ | $\begin{aligned} &>24 \\ & 18-24 \\ &<18\end{aligned}$ | 0 <br> 31 <br> 1 |
| CD3-CD19+ | $>$ | 2 <br> 31 <br> 1 | $\begin{aligned} & >16 \\ 6 & -16 \\ & <6\end{aligned}$ | 0 <br> 34 <br> 3 | $\begin{aligned} & >16 \\ 8 & -16 \\ & <8\end{aligned}$ | 0 <br> 26 <br> 0 | $\begin{aligned} &> \\ & 4-9 \\ &<4\end{aligned}$ | 0 <br> 23 <br> 1 |
| CD3-(CD56 \& CD16)+ | $\begin{aligned} & >14 \\ 7 & -14 \\ & <7\end{aligned}$ | 1 <br> 0 <br> 26 <br> 1 | $\begin{aligned} & >11 \\ 5 & -11 \\ & <5\end{aligned}$ | $\begin{gathered} 0 \\ 24 \\ 2 \end{gathered}$ | $\begin{aligned} & >18 \\ 9 & -18 \\ & <9\end{aligned}$ | 0 <br> 22 <br> 1 | $\begin{aligned} &>19 \\ & 11-19 \\ &<11 \\ & \hline \end{aligned}$ | 1 <br> 17 <br> 1 |
| CD3+ <br> Average | $\begin{aligned} & \\ &>81 \\ & 76-81 \\ &<76\end{aligned}$ | 2 32 3 | $\begin{aligned} &>81 \\ & 75-81 \\ &<\end{aligned}$ | 2 39 1 | $\begin{aligned} & \\ &> \\ & 70 \\ &-74 \\ & \\ &<\end{aligned}$ | 1 26 3 |   <br>  $>$ <br> 71  <br> 17  | 1 <br> 28 <br> 1 |

*The $90 \%$ reference ranges were determined from results provided by participant laboratories which used the monoc lonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).

[^2]Table 2. Range of all 2-color participant laboratory results for the September 1996 shipment for CD16 and CD56 cell markers. Insufficient data were reported by laboratories using the recommended monoclonal antibody panel to enable determination of $90 \%$ reference ranges. The ranges reported in this ta ble are the maximum and minimum values reported by all laboratories using these cell markers.

| Donor Report | $\begin{gathered} \hline \text { HIV } \\ \text { Status } \end{gathered}$ | $\begin{gathered} \hline \text { CD3-/CD16+ } \\ \text { Range } \end{gathered}$ |  |  | $\begin{gathered} \hline \text { CD3-/CD56+ } \\ \text { Range } \end{gathered}$ |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 01 | H | 2 | - | 3 | 1 | - | 1 |
| 02 | M |  | NA |  | 4 | - | 5 |
| 03 | H |  | NA |  | 7 | - | 8 |
| 04 | H |  | NA |  | 1 | - | 2 |
| 05 | H |  | NA |  | 3 | - | 8 |
| 06 | H | 3 | - | 6 | 3 | - | 4 |
| 07 | M | 2 | - | 2 | 1 | - | 3 |
| 08 | L | 19 |  | 19 | 13 |  | 20 |
| 09 | L |  | NA |  | 5 | - | 13 |
| 10 | L | 10 | - | 11 | 6 | - | 10 |
| 11 |  | 1 | - | 1 | 2 | - | 3 |
| 12 | N | 9 | - | 9 | 5 | - | 10 |
| 13 | N | 12 | - | 12 | 5 | - | 17 |
| 14 | N | 4 | - | 8 | 5 | - | 7 |
| 15 | N | 9 | - | 9 | 10 | - | 14 |
| 16 | H |  | NA |  | 4 | - | 10 |
| 17 | H | 2 | - | 2 | 1 | - | 2 |
| 18 | H | 10 | - | 12 | 9 |  | 12 |
| 19 | H | 10 | - | 10 |  | NA |  |
| 20 | H |  | NA |  | 2 | - | 6 |
| 21 | H | 3 | - | 5 | 2 | - | 4 |
| 22 | H | 7 | - | 8 |  | NA |  |
| 23 | L | 3 | - | 3 | 1 | - | 5 |
| 24 | L | 6 | - | 6 | 4 | - | 7 |
| 25 | M | 1 | - | 6 | 2 | - | 4 |
| 26 | L | 3 | - | 4 |  | NA |  |
| 27 | N | 6 | - | 9 | 7 | - | 15 |
| 28 | N | 6 | - | 8 | 3 | - | 15 |
| 29 | N | 4 | - | 6 | 3 | - | 5 |
| 30 | N | 11 | - | 16 | 10 | - | 16 |
| 31 | H |  | NA |  | 8 | - | 14 |
| 32 | H |  | NA |  | 3 | - | 5 |
| 33 | H | 4 |  | 5 | 0 | - | 11 |
| 34 | H | 2 | - | 4 | 2 | - | 4 |
| 35 | H |  | NA |  | 1 | - | 6 |
| 36 | H | 4 | - | 7 | 0 | - | 4 |
| 37 | H |  | NA |  | 2 | - | 7 |
| 38 | L | 22 | - | 23 | 3 | - | 24 |
| 39 | L |  | NA |  | 3 | - | 7 |
| 40 | L | 3 | - | 4 | 1 | - | 17 |
| 41 | L |  | NA |  | 6 | - | 8 |
| 42 | N | 10 | - | 11 | 2 | - | 13 |
| 43 | N | 2 | - | 7 | 4 | - | 8 |
| 44 | N | 15 | - | 15 | 5 | - | 17 |
| 45 | N | 9 | - | 13 | 5 | - | 20 |

Table 3. Percentage of 2-color laboratory results for the September 1996 shipment, by monoc lonal a ntibody manufacturer, that are within the $90 \%$ reference ranges*

Becton-Dickinson ( $\mathrm{N}=117$ )**

| ell Marker | DC | Donor | Num | ber |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (Population) | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| HIV Status*** | H | M | H | H | H | H | M | L | L | L | L | N | N | N | N | H | H | H |
| CD45+ | 100 | 100 | 60 | 100 | 100 | 100 | 100 | 80 | 100 | 90 | 100 | 94 | 94 | 93 | 94 | 100 | 100 | 100 |
| CD14+ | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 89 | 100 | 100 | 100 | 93 | 100 | 50 | 100 | 100 |
| CD3+CD4+ | 100 | 100 | 50 | 100 | 100 | 80 | 100 | 100 | 100 | 80 | 100 | 100 | 94 | 87 | 100 | 100 | 100 | 5 |
| CD3+CD8+ | 100 | 100 | 60 | 100 | 100 | 90 | 100 | 100 | 100 | 80 | 80 | 100 | 88 | 93 | 100 | 67 | 94 | 100 |
| CD3-CD19+ | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 88 | 86 | 100 | 100 | 93 | 100 | 100 | 100 | 100 | 10 |
| CD3-(CD56 \& CD16)+ | +100 | 100 | 50 | 100 | 100 | 100 | 100 | 100 | 90 | 71 | 100 | 77 | 88 | 100 | 86 | 100 | 100 | N A |
| CD3+Average | 100 | 100 | 50 | 100 | 100 | 80 | 100 | 80 | 90 | 89 | 100 | 100 | 93 | 100 | 100 | 67 | 100 | 10 |

Coulter ( $\mathrm{N}=69)^{* *}$

| CDC Donor Number |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (Population) | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| HIV Status*** | H | M | H | H | H | H | M | L | L | L | L | N | N | N | N | H | H | H |
| CD45+ | 100 | 100 | 100 | 100 | 100 | 50 | 100 | 100 | 100 | 67 | 100 | 100 | 100 | 100 | 86 | NA | 100 | 88 |
| CD14+ | 100 | 100 | 100 | 100 | 100 | 100 | 67 | 100 | 100 | 100 | 67 | 100 | 100 | 100 | 71 | NA | 0 | 100 |
| CD3+CD4+ | 100 | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 67 | 100 | 94 | 86 | 100 | NA | 100 | 100 |
| CD3+CD8+ | 93 | 100 | 100 | 88 | 75 | 100 | 50 | 100 | 83 | 100 | 33 | 93 | 94 | 100 | 100 | NA | 100 | 100 |
| CD3-CD19+ | 100 | 100 | 100 | 100 | 100 | NA | 100 | 100 | 100 | 0 | 100 | 50 | 100 | 67 | 75 | NA | NA | 100 |
| CD3-(CD56 \& CD16)+ | + NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | N A |
| CD3+Average | 100 | 100 | 100 | 100 | 67 | 100 | 50 | 100 | 80 | 100 | 0 | 92 | 80 | 100 | 100 | NA | 100 | 100 |

## Other Manufac turers $(\mathrm{N}=68)^{* * * *}$

| Cell Marker | CDC | Dono | um |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (Population) | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| HIV Status*** | H | M | H | H | H | H | M | L | L | L | L | N | N | N | N | H | H | H |
| CD45+ | 100 | 100 | 100 | 100 | 100 | 75 | 100 | 100 | 100 | 83 | 100 | 100 | 100 | 100 | 92 | 100 | 100 | 100 |
| CD14+ | 100 | 100 | 80 | 100 | 100 | 100 | 100 | 75 | 100 | 90 | 100 | 93 | 91 | 100 | 100 | 90 | 100 | 100 |
| CD3+CD4+ | 100 | 100 | 100 | 100 | 100 | 75 | 100 | 100 | 80 | 100 | 100 | 89 | 100 | 91 | 100 | 100 | 100 | 100 |
| CD3+CD8+ | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 78 | 100 | 100 | 100 | 100 | 100 | 100 |
| CD3-CD19+ | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 90 | 86 | 92 | 100 | 100 | 100 | 100 |
| CD3-(CD56 \& CD16)+ | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 83 | 75 | 100 | 100 |
| CD3+Average | 100 | 100 | 100 | 100 | 100 | 75 | 100 | 100 | 100 | 80 | 100 | 75 | 88 | 91 | 100 | 100 | 100 | 100 |

*The $90 \%$ reference ranges were detemined from results provided by participant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
**La boratories using Becton Dic kinson or Coulter monoc lonal a ntibodies exc lusively for all tests.
*** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ )
***Results from laboratories using monoclonal antibodies from more than one manufacturer or from Dako, GenTrak, Immunotech, In-house, Ortho, Pha rmingen, or Sigma.
NA = no data retumed by any laboratory for specified marker

# Table 3. Percentage of 2-colorlaboratory results for the September 1996 shipment, by monoc lonal a ntibody manufacturer, that are within the $90 \%$ reference ranges* 



| C oulter ( $\mathrm{N}=69$ )** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cell Marker | DC | Dono | Num | er |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| (Population) | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 |
| HIV Status*** | H | H | H | H | L | L | M | L | N | N | N | N | H | H | H | H | H | H |
| CD45+ | NA | 100 | 100 | 67 | NA | 100 | 100 | 67 | 100 | 100 | 80 | 80 | 100 | 60 | 50 | 100 | 100 | 100 |
| CD14+ | NA | 100 | 100 | 67 | NA | 50 | 100 | 67 | 100 | 50 | 60 | 88 | 100 | 100 | 100 | 100 | 100 | 100 |
| CD3+CD4+ | NA | 100 | 100 | 100 | NA | 100 | 100 | 100 | 100 | 100 | 100 | 60 | 100 | 100 | 75 | 100 | 100 | 100 |
| CD3+CD8+ | NA | 100 | 100 | 50 | NA | 50 | 86 | 33 | 88 | 50 | 60 | 82 | 90 | 60 | 75 | 100 | 75 | 100 |
| CD3-CD19+ | NA | NA | 100 | NA | NA | NA | 100 | NA | 100 | NA | NA | 100 | 100 | 100 | 100 | 50 | 100 | 100 |
| CD3-(CD56 \& CD16)+ | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 100 | 100 | NA | 100 | NA | N A |
| CD3+Average | NA | 100 | 100 | NA | NA | 100 | 100 | NA | 100 | 100 | 50 | 80 | 38 | 100 | 100 | NA | 75 | 100 |

## Other Manufac turers $(\mathrm{N}=68)^{* * *}$

| Marker CDC Donor Number |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (Population) | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 |
| HIV Status*** | H | H | H | H | L | L | M | L | N | N | N | N | H | H | H | H | H | H |
| CD45+ | 50 | 100 | 67 | 100 | 100 | 100 | 86 | 100 | 94 | 100 | 100 | 91 | 100 | NA | 92 | 100 | 100 | 100 |
| CD14+ | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | NA | 100 | 83 | 100 | 100 |
| CD3+CD4+ | 90 | 100 | 100 | 88 | 100 | 100 | 100 | 100 | 93 | 100 | 90 | 90 | 67 | NA | 90 | 100 | 100 | 100 |
| CD3+CD8+ | 80 | 100 | 100 | 88 | 100 | 86 | 100 | 100 | 93 | 93 | 100 | 80 | 100 | NA | 60 | 100 | 100 | 100 |
| CD3-CD19+ | 100 | 100 | 100 | 100 | 100 | 83 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | NA | 100 | 100 | 100 | 100 |
| CD3-(CD56 \& CD16)+ | 100 | 75 | 100 | 83 | 100 | 100 | 75 | 67 | 82 | 100 | 100 | 100 | 100 | NA | 100 | 100 | 100 | 100 |
| CD3+Average | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 75 | 100 | 100 | 86 | 100 | 100 | NA | 83 | 100 | 100 | $10 \quad 0$ |

*The $90 \%$ reference ranges were detemined from results provided by partic ipant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
**La boratories using Becton Dickinson or Coultermonoclonal antibodies exc lusively for all tests.
*** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ )
***Results from laboratories using monoc lonal a ntibodies from more than one manufacturer or from Dako, GenTrak, Immunotech, In-house, Ortho, Pha rmingen, or Sigma.

NA = no data retumed by any laboratory for specified marker

# Table 3. Percentage of 2-color laboratory results for the September 1996 shipment, by monoc lonal a ntibody manufacturer, that are within the $90 \%$ reference ranges* 

| Becton-Dic kinson ( $\mathrm{N}=117)^{* *}$ |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cell Marker CDC (Population) HIV Status*** | Don | Num |  |  |  |  |  |  |  |
|  | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 |
|  | H | L | L | L | L | N | N | N | N |
| CD45+ | 100 | 100 | 100 | 86 | 100 | 89 | 95 | 94 | 100 |
| CD14+ | 100 | 91 | 100 | 100 | 100 | 94 | 95 | 89 | 100 |
| CD3+CD4+ | 100 | 100 | 100 | 100 | 100 | 83 | 96 | 89 | 93 |
| CD3+CD8+ | 100 | 83 | 90 | 100 | 100 | 89 | 100 | 100 | 100 |
| CD3-CD19+ | 100 | 100 | 100 | 86 | 100 | 86 | 94 | 100 | 100 |
| CD3-(CD56 \& CD16) | 100 | 88 | 88 | 100 | 100 | 100 | 94 | 94 | 90 |
| CD3+Average | 100 | 88 | 100 | 86 | 100 | 73 | 95 | 82 | 100 |


| C oulter ( $\mathrm{N}=69$ )** |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cell Marker CDC Donor Number |  |  |  |  |  |  |  |  |  |
| (Population) | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 |
| HIV Status** | H | L | L | L | L | N | N | N | N |
| CD45+ | 100 | 100 | 100 | 100 | 50 | 100 | 100 | 100 | 86 |
| CD14+ | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| CD3+CD4+ | 100 | 100 | 100 | 100 | 100 | 92 | 93 | 88 | 57 |
| CD3+CD8+ | 100 | 88 | 100 | 100 | 0 | 92 | 80 | 89 | 86 |
| CD3-CD19+ | NA | 100 | 100 | 67 | NA | 100 | 89 | 100 | 67 |
| CD3-(CD56 \& CD16) | NA | 50 | 100 | NA | NA | 50 | 67 | 100 | NA |
| CD3+Average | 100 | 100 | 100 | 100 | 0 | 100 | 100 | 100 | 71 |


| Other Manufa c turers ( $\mathrm{N}=68)^{* * * *}$ |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cell Marker CDC Donor Number |  |  |  |  |  |  |  |  |  |
| (Population) | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 |
| HIV Status*** | H | L | L | L | L | N | N | N | N |
| CD45+ | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| CD14+ | 100 | 100 | 100 | 90 | 100 | 89 | 86 | 89 | 92 |
| CD3+CD4+ | 100 | 100 | 100 | 100 | 100 | 94 | 86 | 100 | 91 |
| CD3+CD8+ | 100 | 88 | 100 | 89 | 100 | 76 | 85 | 71 | 100 |
| CD3-CD19+ | 100 | 100 | 100 | 60 | 100 | 92 | 92 | 100 | 100 |
| CD3-(CD56 \& CD16)- | 100 | 50 | 100 | 86 | 100 | 100 | 100 | 100 | 89 |
| CD3+Average | 100 | 100 | 100 | 100 | 100 | 93 | 83 | 80 | 100 |

*The $90 \%$ reference ranges were determined from results provided by participant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
**La boratories using Becton Dic kinson or Coulter monoc lonal a ntibodies exc lusively for all tests.
** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ )
****Results from laboratories using monoclonal antibodies from more than one manufacturer or from Dako, GenTrak, Immunotech, In-house, Ortho, Pha mingen, or Sigma.
NA = no data retumed by any laboratory for specified marker

Table 4. Percentage of 2-color laboratory results for the September 1996 shipment, by equipment manufacturer, that are within the $90 \%$ reference ranges*

Becton-Dickinson ( $\mathrm{N}=150$ )

| Cell Marker C | CDC | no | Num |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (Population) | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| HIV Status** | H | M | H | H | H | H | M | L | L | L | L | N | N | N | N | H | H | H |
| CD45+ | 100 | 100 | 75 | 100 | 100 | 100 | 100 | 83 | 100 | 100 | 100 | 94 | 94 | 94 | 100 | 100 | 100 | 100 |
| CD14+ | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 90 | 100 | 100 | 100 | 94 | 100 | 50 | 100 | 100 |
| CD3+CD4+ | 100 | 100 | 63 | 100 | 100 | 92 | 100 | 100 | 100 | 90 | 100 | 94 | 93 | 88 | 100 | 100 | 100 | 100 |
| CD3+CD8+ | 100 | 100 | 75 | 100 | 100 | 92 | 100 | 100 | 100 | 90 | 83 | 100 | 93 | 94 | 100 | 67 | 94 | 100 |
| CD3-CD19+ | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 88 | 100 | 93 | 92 | 93 | 100 | 100 | 100 | 100 |
| CD3-(CD56 \& CD16)+ | 100 | 100 | 67 | 100 | 100 | 100 | 100 | 100 | 100 | 83 | 100 | 83 | 92 | 100 | 100 | 100 | 100 | 100 |
| CD3+Average | 100 | 100 | 67100 |  | 100 | $90 \quad 100$ |  | 80 | 88 88 |  | 100100 |  | 92 | 100100 |  | 7 | 100100 |  |
|  | Coulter ( $\mathrm{N}=130$ ) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Cell Marker CDC Donor Number |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| (Population) | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| HIV Status** | H | M | H | H | H | H | M | L | L | L | L | N | N | N | N | H | H | H |
| CD45+ | 100 | 100 | 86 | 100 | 100 | 58 | 100 | 100 | 100 | 69 | 100 | 100 | 100 | 100 | 89 | 100 | 100 | 93 |
| CD14+ | 100 | 100 | 86 | 100 | 100 | 100 | 80 | 92 | 100 | 92 | 100 | 96 | 96 | 100 | 94 | 88 | 67 | 100 |
| CD3+CD4+ | 100 | 100 | 50 | 100 | 100 | 88 | 100 | 100 | 92 | 88 | 100 | 100 | 96 | 93 | 100 | 100 | 100 | 93 |
| CD3+CD8+ | 94 | 100 | 75 | 90 | 83 | 100 | 75 | 100 | 92 | 88 | 75 | 86 | 92 | 100 | 100 | 100 | 100 | 100 |
| CD3-CD19+ | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 89 | 83 | 100 | 77 | 94 | 92 | 92 | 100 | 100 | 100 |
| CD3-(CD56 \& CD16)+ | 100 | 100 | 50 | 100 | 100 | NA | 100 | 100 | 88 | 50 | 100 | 75 | 90 | 100 | 67 | 75 | 100 | 100 |
| CD3+Average | 100 | 100 | 67 | 100 | 83 | 90 | 83 | 100 | 92 | 100 | 67 | 85 | 83 | 93 | 100 | 100 | 100 | $10 \quad 0$ |
|  | Ortho ( $\mathrm{N}=19$ ) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Cell Marker C | CDC Donor Number |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| (Population) | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| HIV Status** | + | M | H | H | H | H | M | L | L | L | L | N | N | N | N | H | H | H |
| CD45+ | 100 | NA | NA | NA | NA | 100 | 100 | 100 | NA | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| CD14+ | 100 | NA | NA | NA | NA | NA | 100 | 100 | NA | NA | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| CD3+CD4+ | 100 | NA | NA | NA | NA | 0 | 100 | 100 | NA | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| CD3+CD8+ | 100 | NA | NA | NA | NA | 100 | 100 | 100 | NA | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| CD3-CD19+ | 100 | NA | NA | NA | NA | 100 | 100 | 100 | NA | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| CD3-(CD56 \& CD16)+ | NA | NA | NA | NA | NA | 100 | NA | NA | NA | 100 | NA | 100 | NA | 100 | NA | NA | 100 | N A |
| CD3+Average | 100 | NA | NA | NA | NA | 0 | 100 | 100 | NA | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | $10 \quad 0$ |

*The $90 \%$ reference ranges were determined from results provided by partic ipant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).

[^3]Table 4. Percentage of 2-color la boratory results for the September 1996 shipment, by equipment manufacturer, that are within the $90 \%$ reference ranges*

Becton-Dickinson ( $\mathrm{N}=150$ )

*The $90 \%$ reference ranges were determined from results provided by partic ipant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).

NA = no data retumed by any laboratory for specified marker

Table 4. Percentage of 2-color laboratory results for the September 1996 shipment, by equipment manufacturer, that are within the $90 \%$ reference ranges*

Becton-Dickinson ( $\mathrm{N}=150$ )

| CDC Donor Number |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (Population) | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 |
| HIV Status** | H | L | L | L | L | N | N | N | N |
| CD45+ | 100 | 100 | 100 | 88 | 100 | 88 | 95 | 94 | 100 |
| CD14+ | 100 | 89 | 100 | 100 | 100 | 94 | 100 | 94 | 100 |
| CD3+CD4+ | 100 | 100 | 100 | 100 | 100 | 82 | 96 | 88 | 93 |
| CD3+CD8+ | 100 | 80 | 91 | 100 | 100 | 82 | 91 | 100 | 100 |
| CD3-CD19+ | 100 | 100 | 100 | 86 | 100 | 79 | 100 | 100 | 100 |
| CD3-(CD56 \& CD16)- | 100 | 83 | 88 | 89 | 100 | 100 | 100 | 100 | 90 |
| CD3+Average | 100 | 89 | 100 | 88 | 100 | 71 | 89 | 80 | 100 |

Coulter ( $\mathrm{N}=130$ )

| CDC Donor Number |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (Population) | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 |
| HIV Status** | H | L | L | L | L | N | N | N | N |
| CD45+ | 100 | 100 | 100 | 100 | 80 | 100 | 100 | 100 | 94 |
| CD14+ | 100 | 100 | 100 | 93 | 100 | 94 | 88 | 88 | 94 |
| CD3+CD4+ | 100 | 100 | 100 | 100 | 100 | 94 | 93 | 94 | 73 |
| CD3+CD8+ | 100 | 88 | 100 | 92 | 50 | 87 | 89 | 82 | 93 |
| CD3-CD19+ | 100 | 100 | 100 | 63 | 100 | 100 | 89 | 100 | 91 |
| CD3-(CD56 \& CD16) | 100 | 67 | 100 | 100 | 100 | 92 | 80 | 86 | 86 |
| CD3+Average | 100 | 100 | 100 | 100 | 50 | 100 | 100 | 93 | 86 |


| Ortho ( $\mathrm{N}=19$ ) |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cell Marker CDC Donor Number |  |  |  |  |  |  |  |  |  |
| (Population) | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 |
| HIV Status** | H | L | L | L | L | N | N | N | N |
| CD45+ | 100 | 100 | 100 | NA | 100 | 100 | 100 | 100 | 100 |
| CD14+ | 100 | 100 | 100 | NA | 100 | 100 | 100 | 100 | 100 |
| CD3+CD4+ | 100 | 100 | 100 | NA | 100 | 100 | 50 | 100 | 100 |
| CD3+CD8+ | 100 | 100 | 100 | NA | 100 | 100 | 100 | 100 | 100 |
| CD3-CD19+ | 100 | 100 | 100 | NA | 100 | 100 | 50 | 100 | 100 |
| CD3-(CD56 \& CD16) | 100 | NA | 100 | NA | 100 | NA | 100 | 100 | 100 |
| CD3+Average | 100 | 100 | 100 | NA | 100 | 100 | 50 | 100 | 100 |

*The $90 \%$ reference ranges were detemined from results provided by partic ipant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Deteminations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
** HIV status: $\mathrm{N}=$ Negative; Positive --- L=Low CD4 ct ( $<200$ ), $\mathrm{M}=\mathrm{Moderate} \mathrm{CD} 4 \mathrm{ct}(>200$ but $<500$ ), H=High CD4 ct ( $>500$ )
$N A=$ no data retumed by a ny laboratory for specified marker

Table 5. Frequency of laboratory results for the September 1996 instrument performance control sample within, above, or below the $90 \%$ reference ranges*

## Event Population

| Green Unstained <br> Orange/Red Unstained | Green Stained <br> Orange/Red Unstained |  |  | Green Unstained <br> Orange/Red Stained | Green Stained <br> Orange/Red Stained |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Range | Frequency | Range | Frequency | Range | Frequency |$|$| Range | Frequency |
| :---: | :---: |
| $<21$ | 12 |

*The $90 \%$ reference ranges were determined from results from the same laboratories whose results were used to determine the $90 \%$ reference ranges for Table 1.

Table 6. Frequency of 3-color laboratory results for the September 1996 shipment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC Donor Number -

| Cell Marker | V Sta |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Population) | 1 | H | 2 | M | 3 | H | 4 | H | 5 | H | 6 | H |
|  | Range | No. ${ }^{\text {a }}$ | Range | No. | Range | No. | Range | No. | Range | No. | Range | No. |
| $\begin{aligned} & \text { CD45+, CD3+, } \\ & \text { CD4+ } \end{aligned}$ | $\begin{array}{r} >53 \\ 39 \end{array} \begin{array}{r} -53 \\ \\ <39 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \end{aligned}$ | $\begin{aligned} & >37 \\ 32 & -37 \\ & <32 \end{aligned}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \end{aligned}$ | $\begin{array}{r} >34 \\ 32-34 \\ \\ <32 \end{array}$ | $\begin{aligned} & 2 \\ & 4 \\ & 0 \end{aligned}$ | NA |  | $\begin{aligned} & >49 \\ 37 & -49 \\ & <37 \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \end{aligned}$ | $\begin{aligned} & >51 \\ 46 & -51 \\ & <46 \end{aligned}$ | 0 2 0 |
| $\begin{aligned} & \text { CD3+, CD4+, } \\ & \text { CD8- } \end{aligned}$ | $\begin{aligned} &>53 \\ & 39-53 \\ &<39 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \end{aligned}$ | $\begin{aligned} & >37 \\ 32 & -37 \\ & <32 \end{aligned}$ | $\begin{aligned} & 0 \\ & 3 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} & >34 \\ 32 & -34 \\ & <32 \end{aligned}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \end{aligned}$ | $\begin{aligned} &>32 \\ & 27-32 \\ &<27 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 6 \\ & 0 \end{aligned}$ | $\begin{aligned} & >49 \\ 37 & -49 \\ & <37 \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \end{aligned}$ | $\begin{aligned} &>51 \\ & 46-51 \\ &<46 \\ & \hline \end{aligned}$ | 0 6 0 |
| $\begin{aligned} & \text { CD45+, CD3+, } \\ & \text { CD8+ } \end{aligned}$ | $\begin{aligned} &>49 \\ & 38-49 \\ &<38 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & >47 \\ 40 & -47 \\ & <40 \end{aligned}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & >44 \\ 36 & -44 \\ & <36 \end{aligned}$ | $\begin{aligned} & 0 \\ & 6 \\ & 0 \\ & \hline \end{aligned}$ | NA |  | $\begin{aligned} & >45 \\ 36 & -45 \\ & <36 \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & >43 \\ 35 & -43 \\ & <35 \end{aligned}$ | 2 0 0 |
| $\begin{aligned} & \text { CD3+, CD4-, } \\ & \text { CD8+ } \end{aligned}$ | $\begin{array}{r} >49 \\ 38-49 \\ \\ <38 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>47 \\ & 40-47 \\ &<40 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{array}{r} >44 \\ 36-44 \\ \\ <36 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \end{aligned}$ | $\begin{aligned} &>53 \\ & 46-53 \\ &<46 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 6 \\ & 0 \end{aligned}$ | $\begin{aligned} &>45 \\ & 36-45 \\ &<36 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \end{aligned}$ | $\begin{array}{r} >43 \\ 35-43 \\ \\ <35 \\ \hline \end{array}$ | 0 6 0 |
| $\begin{aligned} & \text { CD45+, CD3-, } \\ & \text { CD19+ } \end{aligned}$ | $\begin{array}{r} >8 \\ 4-8 \\ \\ <4 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>15 \\ & 10-15 \\ &<10 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & >20 \\ 14 & -20 \\ & <14 \end{aligned}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | NA |  | $\begin{array}{r} >8 \\ 4-8 \\ \\ <4 \end{array}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{array}{r} >9 \\ 6-9 \\ \\ <6 \\ \hline \end{array}$ | 0 <br> 2 <br> 0 |
| $\begin{aligned} & \text { CD45+, CD3-, } \\ & \text { CD(56\&16)+ } \end{aligned}$ | $\begin{array}{r} >3 \\ 1-3 \\ \\ \\ < \end{array}$ | $\begin{aligned} & 2 \\ & 0 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{array}{r}>8 \\ 4-8 \\ <4 \\ \hline\end{array}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $>$ $6-9$ -9 $<6$ | $\begin{aligned} & 2 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | NA |  | NA |  | $\begin{array}{r} >5 \\ 3-5 \\ <3 \\ \hline \end{array}$ | 0 2 0 |
| CD3+ <br> Average | $\begin{array}{r} >95 \\ 88 \end{array} \quad-95$ | $\begin{aligned} & 0 \\ & 6 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>80 \\ & 74-80 \\ &<74 \\ & \hline \end{aligned}$ | $\begin{aligned} & 2 \\ & 2 \\ & 0 \end{aligned}$ | $\begin{aligned} &>74 \\ & 67-74 \\ &<67 \\ & \hline \end{aligned}$ | $\begin{aligned} & 1 \\ & 7 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>84 \\ & 78-84 \\ &<78 \\ & \hline \end{aligned}$ | $\begin{aligned} & 2 \\ & 0 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>91 \\ & 86-91 \\ &<86 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>91 \\ & 88-91 \\ &<88 \\ & \hline \end{aligned}$ | 0 6 0 |

*The $90 \%$ reference ranges were determined from the 2-color results provided by partic ipant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell
Determinations in Persons with Human Immunodefic ienc y Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), $M=$ Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ )
${ }^{\Delta}$ = frequency of laboratories
NA = no data retumed by any laboratory forspecified marker

Table 6. Frequency of 3-color laboratory results for the September 1996 shipment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC Donor Number -

| Cell Marker (Population) | HIV Status** |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 7 - M |  | $8-L$ |  | $9-\mathrm{L}$ |  | $10-\mathrm{L}$ |  | $11-\mathrm{L}$ |  | 12 |  |
|  | Range | No. ${ }^{\text {a }}$ | Range | No | Range | No. | Range | No | Range | No. | Range | No. |
| CD45+, CD3+, CD4+ | $\begin{aligned} &>48 \\ & 38-48 \\ &<38 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & >22 \\ 15 & -22 \\ & <15 \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \end{aligned}$ | $\begin{array}{r} >3 \\ 1-3 \\ \\ < \end{array}$ | $\begin{aligned} & 0 \\ & 3 \\ & 0 \end{aligned}$ | $\begin{aligned} & >14 \\ 10 & -14 \\ & <10 \end{aligned}$ | 0 <br> 4 <br> 0 | $\begin{aligned} &>16 \\ & 10-16 \\ &<10 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>40 \\ & 29-40 \\ &<29 \\ & \hline \end{aligned}$ | 0 <br> 6 <br> 0 |
| $\begin{aligned} & \text { CD3+, CD4+, } \\ & \text { CD8- } \end{aligned}$ | $\begin{aligned} &>48 \\ & 38-48 \\ &<38 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & >22 \\ 15 & -22 \\ & <15 \end{aligned}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{array}{r} >3 \\ 1-3 \\ \\ \\ < \end{array}$ | $\begin{aligned} & 0 \\ & 3 \\ & 0 \end{aligned}$ | $\begin{aligned} &>14 \\ & 10-14 \\ &<10 \\ & \hline \end{aligned}$ | 0 <br> 6 <br> 0 | $\begin{aligned} &>16 \\ & 10-16 \\ &<10 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 1 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>40 \\ & 29-40 \\ &<29 \\ & \hline \end{aligned}$ | 1 <br> 9 <br> 0 |
| CD45+, CD3+, CD8+ | $\begin{aligned} &>50 \\ & 44-50 \\ &<44 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>52 \\ & 40-52 \\ &<40 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{array}{r} >42 \\ 34-42 \\ \\ <34 \end{array}$ | $\begin{aligned} & 1 \\ & 2 \\ & 0 \end{aligned}$ | $\begin{aligned} &>65 \\ & 57-65 \\ &<57 \\ & \hline \end{aligned}$ | 0 3 1 | $\begin{array}{r} >75 \\ 71 \end{array} \begin{array}{r} >75 \\ \\ < \end{array}$ | $\begin{aligned} & 1 \\ & 1 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & >29 \\ 21 & -29 \\ & <21 \end{aligned}$ | 1 <br> 5 <br> 0 |
| $\begin{aligned} & \text { CD3+, CD4-, } \\ & \text { CD8+ } \end{aligned}$ | $\begin{aligned} &>50 \\ & 44-50 \\ &<44 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 1 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} &>52 \\ & 40-52 \\ &<40 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{array}{r} >42 \\ 34-42 \\ \\ <34 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 3 \\ & 0 \end{aligned}$ | $\begin{aligned} &>65 \\ & 57-65 \\ &<57 \\ & \hline \end{aligned}$ | 0 <br> 6 <br> 0 | $\begin{array}{r} >75 \\ 71-75 \\ \\ <71 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} & >29 \\ 21 & -29 \\ & <21 \end{aligned}$ | $\begin{gathered} 0 \\ 10 \\ 0 \\ \hline \end{gathered}$ |
| $\begin{aligned} & \text { CD45+, CD3-, } \\ & \text { CD19+ } \end{aligned}$ | $\begin{array}{r} >6 \\ 2-6 \\ <2 \\ \hline \end{array}$ | $\begin{aligned} & 1 \\ & 3 \\ & 0 \end{aligned}$ | $\begin{aligned} & >13 \\ 6 & -13 \\ & <6 \end{aligned}$ | $\begin{aligned} & 0 \\ & 1 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{array}{r} >44 \\ 32-44 \\ <32 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \end{aligned}$ | $\begin{aligned} &>16 \\ & 9-16 \\ &<9 \\ & \hline \end{aligned}$ | 0 <br> 3 <br> 0 | $\begin{array}{r} >8 \\ 2-8 \\ \\ <2 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & >24 \\ 15 & -24 \\ & <15 \end{aligned}$ | 0 <br> 4 <br> 0 |
| $\begin{aligned} & \text { CD45+, CD3-, } \\ & \text { CD(56\&16)+ } \end{aligned}$ | $\begin{array}{r} >4 \\ 2-4 \\ <2 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 3 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} &>22 \\ & 14-22 \\ &<14 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 1 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>15 \\ & 9-15 \\ &<9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 1 \\ & 0 \end{aligned}$ | $\begin{aligned} & >13 \\ 8 & -13 \\ & <8 \end{aligned}$ | 0 3 0 | $\begin{array}{r} >3 \\ 2-3 \\ <2 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 1 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} &<11 \\ & 8-11 \\ &<8 \\ & \hline \end{aligned}$ | 1 <br> 3 <br> 0 |
| CD3+ <br> Average | $\begin{aligned} &>93 \\ & 86-93 \\ &<86 \\ & \hline \end{aligned}$ | 0 8 0 | $\begin{aligned} &>71 \\ & 60-71 \\ &<60 \\ & \hline \end{aligned}$ | 0 4 0 | $\begin{aligned} &>53 \\ & 44-53 \\ &<44 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>76 \\ & 70-76 \\ &<70 \\ & \hline \end{aligned}$ | 1 7 0 | $\begin{aligned} &>93 \\ & 88-93 \\ &<88 \\ & \hline \end{aligned}$ | 1 <br> 3 <br> 0 | $\begin{aligned} &>77 \\ & 67-77 \\ &<67 \\ & \hline \end{aligned}$ | 1 11 1 |

*The $90 \%$ reference ranges were determined from the 2-color results provided by partic ipant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic ienc y Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).

[^4]${ }^{\Delta}=$ frequency of laboratories $\quad N A=$ no data retumed by a ny laboratory for spec ified marker

Table 6. Frequency of 3-color laboratory results for the September 1996 shipment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC Donor Number -

| Cell Marker | Sta |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Population) | 13 | N | 14 | N | 15 | N | 16 | H | 17 | H | 18 | H |
|  | Range | No. ${ }^{\text {a }}$ | Range | No. | Range | No. | Range | No. | Range | No. | Range | No. |
| $\begin{aligned} & \text { CD45+, CD3+, } \\ & \text { CD4+ } \end{aligned}$ | $\begin{aligned} &>53 \\ & 46-53 \\ &<46 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 5 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & >67 \\ 60 & -67 \\ & <60 \end{aligned}$ | $\begin{aligned} & 0 \\ & 5 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{array}{r} >42 \\ 33-42 \\ <33 \end{array}$ | $\begin{aligned} & 0 \\ & 6 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>41 \\ & 32-41 \\ &<32 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 8 \\ & 0 \end{aligned}$ | $\begin{aligned} &>33 \\ & 27-33 \\ &<27 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \end{aligned}$ | $\begin{aligned} & >52 \\ 46 & -52 \\ & <46 \end{aligned}$ | 0 8 0 |
| $\begin{aligned} & \text { CD3+, CD4+, } \\ & \text { CD8- } \end{aligned}$ | $\begin{aligned} &>53 \\ & 46-53 \\ &<46 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 7 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & >67 \\ 60 & -67 \\ & <60 \end{aligned}$ | $\begin{aligned} & 2 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{array}{r} >42 \\ 33-42 \\ <33 \end{array}$ | $\begin{aligned} & 0 \\ & 5 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{array}{r} >41 \\ 32-41 \\ <32 \end{array}$ | $\begin{aligned} & 1 \\ & 3 \\ & 0 \end{aligned}$ | $\begin{aligned} &>33 \\ & 27-33 \\ &<27\end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \end{aligned}$ | NA |  |
| $\begin{aligned} & \text { CD45+, CD3+, } \\ & \text { CD8+ } \end{aligned}$ | $\begin{aligned} &>27 \\ & 22-27 \\ &<22 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 5 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & >21 \\ 16 & -21 \\ & <16 \end{aligned}$ | $\begin{aligned} & 1 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & >31 \\ 22 & -31 \\ & <22 \end{aligned}$ | $\begin{aligned} & 0 \\ & 6 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>50 \\ & 40-50 \\ &<40 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 8 \\ & 0 \end{aligned}$ | $\begin{aligned} & >60 \\ 48 & -60 \\ & <48 \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{array}{r} >22 \\ 13-22 \\ \end{array} \begin{array}{r} >13 \end{array}$ | $\begin{aligned} & 0 \\ & 6 \\ & 0 \end{aligned}$ |
| $\begin{aligned} & \text { CD3+, CD4-, } \\ & \text { CD8+ } \end{aligned}$ | $\begin{aligned} &>27 \\ & 22-27 \\ &<22 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 6 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} &>21 \\ & 16-21 \\ &<16 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 6 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>31 \\ & 22-31 \\ &<22 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 5 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>50 \\ & 40-50 \\ &<40 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ |  $>60$ <br> $48-60$  <br>  $<48$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \end{aligned}$ | NA |  |
| $\begin{aligned} & \text { CD45+, CD3-, } \\ & \text { CD19+ } \end{aligned}$ | $\begin{aligned} & >13 \\ 9 & -13 \\ & <9 \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{array}{r} >8 \\ 6-8 \\ \\ <6 \\ \hline \end{array}$ | $\begin{aligned} & 2 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & >20 \\ 15 & -20 \\ & <15 \end{aligned}$ | $\begin{aligned} & 0 \\ & 5 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{array}{r} >9 \\ 6-9 \\ \\ <6 \\ \hline \end{array}$ | $\begin{aligned} & 1 \\ & 7 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>10 \\ & 7-10 \\ &<7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>22 \\ & 17-22 \\ &<17 \\ & \hline \end{aligned}$ | 0 <br> 6 <br> 0 |
| $\begin{aligned} & \text { CD45+, CD3-, } \\ & \text { CD(56\&16)+ } \end{aligned}$ | $\begin{aligned} &>17 \\ & 11-17 \\ &<11 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{array}{r} >8 \\ 5-8 \\ \\ <5 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>16 \\ & 11-16 \\ &<11 \\ & \hline \end{aligned}$ | $\begin{aligned} & 1 \\ & 3 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{array}{r} >6 \\ 5-6 \\ <5 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 3 \\ & 3 \end{aligned}$ | $\begin{array}{r} >3 \\ 2-3 \\ \\ <2 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>12 \\ & 10-12 \\ &<10 \\ & \hline \end{aligned}$ | 0 6 0 |
| CD3+ <br> Average | $\begin{array}{r} >78 \\ 73-78 \\ \\ \\ <773 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 8 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>89 \\ & 80-89 \\ &<80 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 9 \\ & 0 \end{aligned}$ | $\begin{aligned} &>71 \\ & 63-71 \\ &<63 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 11 \\ 0 \end{gathered}$ | $\begin{array}{rr}  & >89 \\ 84 & -89 \\ & <84 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 8 \\ & 1 \end{aligned}$ | $\begin{aligned} &>91 \\ & 84-91 \\ &<84 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \end{aligned}$ | $\begin{aligned} &>71 \\ & 65-71 \\ &<65 \\ & \hline \end{aligned}$ | 0 8 0 |

*The $90 \%$ reference ranges were determined from the 2-color results provided by partic ipant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell
Determinations in Persons with Human Immunodefic ienc y Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), $M=$ Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ )
${ }^{\Delta}$ = frequency of laboratories
NA = no data retumed by any laboratory forspecified marker

Table 6. Frequency of 3-color laboratory results for the September 1996 shipment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC Donor Number -

| Cell Marker | HIV Status* |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (Population) | 19 - | H | 20 | H | 21 | H | 22 | H | 23 | L | 24 | L |
|  | Range | No. ${ }^{\text {a }}$ | Range | No. | Range | No. | Range | No. | Range | No. | Range | No. |
| $\begin{aligned} & \text { CD45+, CD3+, } \\ & \text { CD4+ } \end{aligned}$ | $\begin{array}{r} >39 \\ 33-39 \\ <\quad 33 \\ \hline \end{array}$ | $\begin{aligned} & 2 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>46 \\ & 33-46 \\ &<33 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & >53 \\ 45 & -53 \\ & <45\end{aligned}$ | $\begin{aligned} & 0 \\ & 8 \\ & 0 \end{aligned}$ | NA |  | $\begin{array}{r} >8 \\ 6-8 \\ \\ <6 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 7 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{array}{r} >8 \\ 7-8 \\ \\ <7 \\ \hline \end{array}$ | 0 <br> 1 <br> 1 |
| $\begin{aligned} & \text { CD3+, CD4+, } \\ & \text { CD8- } \end{aligned}$ | NA |  | $\begin{aligned} &>46 \\ & 33-46 \\ &<33 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & >53 \\ 45 & -53 \\ & <45 \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \end{aligned}$ | NA |  | $\begin{array}{r} >8 \\ 6-8 \\ \\ <6 \end{array}$ | $\begin{aligned} & 1 \\ & 1 \\ & 0 \end{aligned}$ | $\begin{array}{r} >8 \\ 7-8 \\ <7 \end{array}$ | 1 1 0 |
| $\begin{aligned} & \text { CD45+, CD3+, } \\ & \text { CD8+ } \end{aligned}$ | $\begin{aligned} &>38 \\ & 34-38 \\ &<34 \\ & \hline \end{aligned}$ | $\begin{aligned} & 2 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>41 \\ & 33-41 \\ &<33 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & >46 \\ 35 & -46 \\ & <35 \end{aligned}$ | $\begin{aligned} & 0 \\ & 8 \\ & 0 \\ & \hline \end{aligned}$ | NA |  | $\begin{aligned} &>85 \\ & 77-85 \\ &<77 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 7 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>67 \\ & 57-67 \\ &<57 \\ & \hline \end{aligned}$ | 0 2 0 |
| $\begin{aligned} & \text { CD3+, CD4-, } \\ & \text { CD8+ } \end{aligned}$ | NA |  | $>$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>46 \\ & 35-46 \\ &<35 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \end{aligned}$ | NA |  | $\begin{aligned} &>85 \\ & 77-85 \\ &<77 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 1 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} & >67 \\ 57 & -67 \\ & <57 \end{aligned}$ | 0 <br> 1 <br> 1 |
| $\begin{aligned} & \text { CD45+, CD3-, } \\ & \text { CD19+ } \end{aligned}$ | $\begin{aligned} & >16 \\ 11 & -16 \\ & <11\end{aligned}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | NA |  | $\begin{aligned} & >10 \\ 6 & -10 \\ & <6\end{aligned}$ | $\begin{aligned} & 0 \\ & 6 \\ & 0 \end{aligned}$ | NA |  | $\begin{array}{r} >6 \\ 4-6 \\ <4 \end{array}$ | $\begin{aligned} & 0 \\ & 6 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{array}{r} >25 \\ 15-25 \\ \\ <15 \end{array}$ | 0 1 0 |
| $\begin{aligned} & \text { CD45+, CD3-, } \\ & \text { CD(56\&16)+ } \end{aligned}$ | $\begin{aligned} &>14 \\ & 7-14 \\ &<7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | NA |  | $>7$ $3-7$ $<$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \end{aligned}$ | NA |  | $\begin{array}{r} >6 \\ 2-6 \\ \\ <2 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 4 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} &>13 \\ & 7-13 \\ &<7 \\ & \hline \end{aligned}$ | 0 <br> 1 <br> 0 |
| CD3+ <br> Average | $\begin{aligned} &>76 \\ & 69-76 \\ &<69 \\ & \hline \hline \end{aligned}$ | $\begin{aligned} & 2 \\ & 2 \\ & 0 \\ & \hline \hline \end{aligned}$ | $\begin{array}{r} >84 \\ 74 \end{array} \quad-84$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>92 \\ & 86-92 \\ &<86 \\ & \hline \end{aligned}$ | $\begin{aligned} & 1 \\ & 3 \\ & 0 \\ & \hline \end{aligned}$ | NA |  | $\begin{aligned} &>92 \\ & 86-92 \\ &<86 \\ & \hline \end{aligned}$ | $\begin{aligned} & 1 \\ & 5 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>75 \\ & 64-75 \\ &<64 \\ & \hline \end{aligned}$ | 0 3 0 |

*The $90 \%$ reference ranges were determined from the 2-color results provided by partic ipant laboratories which used the monoc lonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic ienc y Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).

[^5]Table 6. Frequency of 3-color laboratory results for the September 1996 shipment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC Donor Number -

| Cell Marker | IV Status |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (Population) | 25 | M | 26 | L | 27 | N | 28 | N | 29 | N | 30 | N |
|  | Range | No. ${ }^{\text {a }}$ | Range | No. | Range | No. | Range | No. | Range | No. | Range | No. |
| $\begin{aligned} & \text { CD45+, CD3+, } \\ & \text { CD4+ } \end{aligned}$ | $\begin{aligned} &>14 \\ & 9-14 \\ &<9 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 8 \\ & 0 \\ & \hline \end{aligned}$ | NA |  | $\begin{aligned} & >55 \\ 49 & -55 \\ & <49 \end{aligned}$ | $\begin{gathered} 0 \\ 14 \\ 1 \end{gathered}$ | $\begin{array}{r} >45 \\ 37-45 \\ \\ <37 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 9 \\ & 0 \end{aligned}$ | $\begin{aligned} & >62 \\ 55 & -62 \\ & <55 \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \end{aligned}$ | $\begin{aligned} & >45 \\ 40 & -45 \\ & <40 \end{aligned}$ | 0 <br> 8 <br> 0 |
| $\begin{aligned} & \text { CD3+, CD4+, } \\ & \text { CD8- } \end{aligned}$ | $\begin{aligned} & >14 \\ 9 & -14 \\ & <9\end{aligned}$ | $\begin{aligned} & 0 \\ & 1 \\ & 0 \\ & \hline \end{aligned}$ | NA |  | $\begin{aligned} & >55 \\ 49 & -55 \\ & <49 \end{aligned}$ | $\begin{aligned} & 0 \\ & 3 \\ & 0 \end{aligned}$ | $\begin{array}{r} >45 \\ 37-45 \\ \\ <37 \end{array}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \end{aligned}$ | $\begin{aligned} &>62 \\ & 55-62 \\ &<55 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \end{aligned}$ | $\begin{aligned} & >45 \\ 40 & -45 \\ & <40 \end{aligned}$ | 0 1 0 |
| $\begin{aligned} & \text { CD45+, CD3+, } \\ & \text { CD8+ } \end{aligned}$ | $\begin{array}{r} >76 \\ 67-76 \\ \\ \\ < \end{array}$ | $\begin{aligned} & 4 \\ & 3 \\ & 0 \\ & \hline \end{aligned}$ | NA |  | $\begin{aligned} &>33 \\ & 26-33 \\ &<26 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 14 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} &>38 \\ & 32-38 \\ &<32 \\ & \hline \end{aligned}$ | $\begin{aligned} & 1 \\ & 8 \\ & 0 \end{aligned}$ | $\begin{aligned} & >28 \\ 22 & -28 \\ & <22 \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & >26 \\ 22 & -26 \\ & <22 \end{aligned}$ | $\begin{aligned} & 0 \\ & 7 \\ & 0 \\ & \hline \end{aligned}$ |
| $\begin{aligned} & \text { CD3+, CD4-, } \\ & \text { CD8+ } \end{aligned}$ | $\begin{aligned} &>76 \\ & 67-76 \\ &<67 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 0 \\ & 1 \\ & \hline \end{aligned}$ | NA |  | $\begin{array}{r} >33 \\ 26-33 \\ \\ <26 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 2 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{array}{r} >38 \\ 32-38 \\ < \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{array}{r} >28 \\ 22-28 \\ <22 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 1 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{array}{r} >26 \\ 22-26 \\ \\ <22 \\ \hline \end{array}$ | 0 1 0 |
| $\begin{aligned} & \text { CD45+, CD3-, } \\ & \text { CD19+ } \end{aligned}$ | $\begin{aligned} & >14 \\ 8 & -14 \\ & <8\end{aligned}$ | $\begin{aligned} & 0 \\ & 1 \\ & 5 \\ & \hline \end{aligned}$ | NA |  | $\begin{array}{r} >8 \\ 5-8 \\ \\ <5 \\ \hline \end{array}$ | $\begin{gathered} 1 \\ 11 \\ 0 \\ \hline \end{gathered}$ | $\begin{aligned} & >13 \\ 8 & -13 \\ & <8 \end{aligned}$ | $\begin{aligned} & 0 \\ & 7 \\ & 0 \end{aligned}$ | $\begin{aligned} & >11 \\ 7 & -11 \\ & <7 \end{aligned}$ | $\begin{aligned} & 0 \\ & 1 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & >22 \\ 15 & -22 \\ & <15 \end{aligned}$ | 0 <br> 6 <br> 0 |
| $\begin{aligned} & \text { CD45+, CD3-, } \\ & \text { CD(56\&16)+ } \end{aligned}$ | $\begin{array}{r} >4 \\ 2-4 \\ <2 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | NA |  | $\begin{aligned} &>10 \\ & 7-10 \\ &<7 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 9 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & >11 \\ 7 & -11 \\ & <7 \end{aligned}$ | $\begin{aligned} & 0 \\ & 6 \\ & 0 \end{aligned}$ | $\begin{array}{r} >7 \\ 5-7 \\ <5 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 1 \\ & \hline \end{aligned}$ | $\begin{aligned} &>20 \\ & 11-20 \\ &<11 \\ & \hline \end{aligned}$ | 0 <br> 4 <br> 0 |
| CD3+ <br> Average | $>$ | $\begin{aligned} & 4 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | NA |  | $\begin{aligned} &>87 \\ & 83-87 \\ &<83 \\ & \hline \end{aligned}$ | $\begin{gathered} 0 \\ 12 \\ 1 \\ \hline \end{gathered}$ | $\begin{aligned} &>85 \\ & 74-85 \\ &<74 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 9 \\ & 0 \end{aligned}$ | $\begin{aligned} &>88 \\ & 81-88 \\ &<81 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 3 \\ & 0 \end{aligned}$ | $\begin{aligned} &>70 \\ & 63-70 \\ &<63 \\ & \hline \end{aligned}$ | 0 6 0 |

*The $90 \%$ reference ranges were determined from the 2-color results provided by partic ipant laboratories which used the monoc lonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell
Determinations in Persons with Human Immunodefic ienc y Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ )
${ }^{\Delta}$ = frequency of laboratories
NA = no data retumed by any laboratory forspecified marker

Table 6. Frequency of 3-color laboratory results for the September 1996 shipment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC Donor Number -

| Cell Marker (Population) | HIV Status** |  |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $31-\mathrm{H}$ |  | $32-\mathrm{H}$ |  | $33-\mathrm{H}$ |  | $34-\mathrm{H}$ |  | $35-\mathrm{H}$ |  | $36-\mathrm{H}$ |  |
|  | Range | No. ${ }^{\text {a }}$ | Range | No. | Range | No | Range | No. | Range | No. | Range | No. |
| $\begin{aligned} & \text { CD45+, CD3+, } \\ & \text { CD4+ } \end{aligned}$ | NA |  | $\begin{aligned} &>32 \\ & 27-32 \\ &<27\end{aligned}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | NA |  | $\begin{array}{r} >36 \\ 32-36 \\ <32 \end{array}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>39 \\ & 24-39 \\ &<24 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>45 \\ & 32-45 \\ &<32 \\ & \hline \end{aligned}$ | 0 6 0 |
| $\begin{aligned} & \text { CD3+, CD4+, } \\ & \text { CD8- } \end{aligned}$ | NA |  | $\begin{aligned} &>32 \\ & 27-32 \\ &<27 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>30 \\ & 27-30 \\ &<27 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 1 \\ & 1 \\ & \hline \end{aligned}$ | NA |  | $\begin{aligned} &>39 \\ & 24-39 \\ &<24 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>45 \\ & 32-45 \\ &<32 \\ & \hline \end{aligned}$ | 2 <br> 4 <br> 0 |
| $\begin{aligned} & \text { CD45+, CD3+, } \\ & \text { CD8+ } \end{aligned}$ | NA |  |  $>53$ <br> $47-53$  <br>  $<47$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | NA |  | $\begin{aligned} &>58 \\ & 53-58 \\ &<53 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>56 \\ & 49-56 \\ &<49 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 1 \\ & 3 \\ & \hline \end{aligned}$ | $\begin{aligned} & >52 \\ 39 & -52 \\ & <39 \end{aligned}$ | 0 <br> 6 <br> 0 |
| $\begin{aligned} & \text { CD3+, CD4-, } \\ & \text { CD8+ } \end{aligned}$ | NA |  |  $>53$ <br> $47-53$  <br>  $<47$ | 0 <br> 2 <br> 0 |  $>52$ <br> $47-52$  <br>  $<47$ | $\begin{aligned} & 1 \\ & 1 \\ & 0 \\ & \hline \end{aligned}$ | NA |  | $\begin{array}{r} >56 \\ 49-56 \\ \\ <49 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 2 \\ & 2 \end{aligned}$ | $\begin{array}{r} >52 \\ 39-52 \\ \\ <39 \end{array}$ | 0 <br> 4 <br> 2 |
| $\begin{aligned} & \text { CD45+, CD3-, } \\ & \text { CD19+ } \end{aligned}$ | NA |  |  $>15$ <br> $10-15$  <br>  $<10$ | $\begin{aligned} & 0 \\ & 0 \\ & 2 \\ & \hline \end{aligned}$ | NA |  | $>6$ $2-6$ $<$ | 0 <br> 2 <br> 0 | $\begin{array}{r} >9 \\ 2-9 \\ \\ <2 \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} &>10 \\ & 2-10 \\ &<2 \\ & \hline \end{aligned}$ | 0 <br> 4 <br> 0 |
| $\begin{aligned} & \text { CD45+, CD3-, } \\ & \text { CD(56\&16)+ } \end{aligned}$ | NA |  | 1 | $\begin{aligned} & 0 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | NA |  | $>5$ $3-5$ $<$ | 0 <br> 2 <br> 0 | $\begin{array}{r} >6 \\ 3-6 \\ < \\ \hline \end{array}$ | $\begin{aligned} & 0 \\ & 0 \\ & 2 \\ & \hline \end{aligned}$ | $\begin{array}{r} >9 \\ 1-9 \\ \\ \\ < \end{array}$ | 0 <br> 4 <br> 0 |
| CD3+ <br> Average | NA |  | NA |  | $\begin{aligned} &>83 \\ & 78-83 \\ &<78 \\ & \hline \end{aligned}$ | 1 1 0 | $\begin{array}{r} >93 \\ 88 \end{array} \quad-93$ | 0 2 0 | $\begin{aligned} & >93 \\ 85 & -93 \\ & <85 \end{aligned}$ | $\begin{aligned} & 0 \\ & 4 \\ & 2 \\ & \hline \hline \end{aligned}$ | $\begin{aligned} &>87 \\ & 82-87 \\ &<82 \\ & \hline \hline \end{aligned}$ | 0 10 0 |

*The $90 \%$ reference ranges were determined from the 2 -color results provided by partic ipant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).
** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ )
${ }^{\Delta}=$ frequency of laboratories $\quad N A=$ no data retumed by a ny laboratory for spec ified marker

Table 6. Frequency of 3-color laboratory results for the September 1996 shipment, by cell marker, within, above, or below the $90 \%$ reference ranges*

CDC Donor Number -

*The $90 \%$ reference ranges were determined from the 2 -color results provided by participant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelinesfor the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic iency Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).

[^6]Table 6. Frequency of 3-color laboratory results for the September 1996 shipment, by cell marker, within, above, or below the $90 \%$ reference ranges*

| Cell Marker (Population) | CDC Donor Number HIV Status** |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $42-\mathrm{N}$ |  | 43 | N | 44 | N | 45 | N |
|  | Range | No. ${ }^{\wedge}$ | Range | No. | Range | No. | Range | No. |
| $\begin{aligned} & \text { CD45+, CD3+, } \\ & \text { CD4+ } \end{aligned}$ | $\begin{aligned} & >57 \\ 50 & -57 \\ & <50 \end{aligned}$ | $\begin{aligned} & 1 \\ & 3 \\ & 0 \end{aligned}$ | $\begin{aligned} &>63 \\ & 55-63 \\ &<55 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 5 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{array}{r} >54 \\ 47-54 \\ \\ <47 \end{array}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \end{aligned}$ | $\begin{array}{r} >54 \\ 49-54 \\ <49 \end{array}$ | 0 <br> 7 <br> 0 |
| $\begin{aligned} & \text { CD3+, CD4+, } \\ & \text { CD8- } \end{aligned}$ | $\begin{aligned} & >57 \\ 50 & -57 \\ & <50 \end{aligned}$ | $\begin{aligned} & 0 \\ & 3 \\ & 1 \end{aligned}$ | $\begin{aligned} & >63 \\ 55 & -63 \\ & <55 \end{aligned}$ | $\begin{aligned} & 0 \\ & 3 \\ & 0 \end{aligned}$ | $\begin{aligned} & >54 \\ 47 & -54 \\ & <47 \end{aligned}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \end{aligned}$ | $\begin{aligned} & >54 \\ 49 & -54 \\ & <49 \end{aligned}$ | 1 <br> 5 <br> 1 |
| $\begin{aligned} & \text { CD45+, CD3+, } \\ & \text { CD8+ } \end{aligned}$ | $\begin{array}{r} >28 \\ 22-28 \\ \\ <22 \end{array}$ | $\begin{aligned} & 0 \\ & 3 \\ & 1 \end{aligned}$ | $\begin{aligned} &>24 \\ & 17-24 \\ &<17 \\ & \hline \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 2 \end{aligned}$ | $\begin{aligned} & >23 \\ 18 & -23 \\ & <18 \end{aligned}$ | $\begin{aligned} & 0 \\ & 3 \\ & 0 \end{aligned}$ | $\begin{aligned} & >24 \\ 18 & -24 \\ & <18 \end{aligned}$ | 0 7 0 |
| $\begin{aligned} & \text { CD3+, CD4-, } \\ & \text { CD8+ } \end{aligned}$ | $\begin{aligned} & >28 \\ 22 & -28 \\ & <22 \end{aligned}$ | $\begin{aligned} & 1 \\ & 3 \\ & 0 \end{aligned}$ | $\begin{aligned} & >24 \\ 17 & -24 \\ & <17 \end{aligned}$ | $\begin{aligned} & 0 \\ & 1 \\ & 2 \end{aligned}$ | $\begin{aligned} & >23 \\ 18 & -23 \\ & <18 \end{aligned}$ | $\begin{aligned} & 0 \\ & 3 \\ & 1 \end{aligned}$ | $\begin{aligned} & >24 \\ 18 & -24 \\ & <18 \end{aligned}$ | 1 6 0 |
| $\begin{aligned} & \text { CD45+, CD3-, } \\ & \text { CD19+ } \end{aligned}$ | $\begin{array}{r} >9 \\ 6-9 \\ <6 \end{array}$ | $\begin{aligned} & 1 \\ & 2 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & >16 \\ 6 & -16 \\ & <6 \end{aligned}$ | $\begin{aligned} & 0 \\ & 4 \\ & 0 \end{aligned}$ | $\begin{aligned} & >16 \\ 8 & -16 \\ & <8 \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \end{aligned}$ | $\begin{array}{r} >9 \\ 4-9 \\ <4 \end{array}$ | 0 5 0 |
| $\begin{aligned} & \text { CD45+, CD3-, } \\ & \text { CD(56\&16)+ } \end{aligned}$ | $\begin{aligned} & >14 \\ 7 & -14 \\ & <7 \end{aligned}$ | $\begin{aligned} & 0 \\ & 3 \\ & 0 \end{aligned}$ | $\begin{aligned} & >11 \\ 5 & -11 \\ & <5 \end{aligned}$ | $\begin{aligned} & 0 \\ & 3 \\ & 0 \end{aligned}$ | $\begin{aligned} & >18 \\ 9 & -18 \\ & <9 \end{aligned}$ | $\begin{aligned} & 0 \\ & 2 \\ & 0 \end{aligned}$ | $\begin{aligned} & >19 \\ 11 & -19 \\ & <11 \end{aligned}$ | 0 3 1 |
| CD3+ <br> Average | $\begin{aligned} & >81 \\ 76 & -81 \\ & <76 \end{aligned}$ | $\begin{aligned} & 0 \\ & 7 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{aligned} & >81 \\ 75 & -81 \\ & <75 \end{aligned}$ | $\begin{aligned} & 0 \\ & 3 \\ & 0 \\ & \hline \end{aligned}$ | $\begin{array}{r} >74 \\ 70-74 \\ \\ <70 \end{array}$ | 1 3 1 | $\begin{aligned} &>77 \\ & 71-77 \\ &<71 \\ & \hline \end{aligned}$ | 0 10 0 |

*The $90 \%$ reference ranges were determined from the 2 -color results provided by participant laboratories which used the monoclonal antibody panel recommended in "1994 Revised Guidelines for the Performance of CD4+T-Cell Determinations in Persons with Human Immunodefic ienc y Virus (HIV) Infection," MMWR 1994; 43(No.RR-3).

[^7]
[^0]:    ${ }^{\Delta}=$ frequency of laboratories

[^1]:    ** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ ) ${ }^{\Delta}=$ frequency of laboratories

[^2]:    ** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ )
    ${ }^{\Delta}=$ frequency of laboratories

[^3]:    ** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ )
    $N A=$ no data retumed by any laboratory for specified marker

[^4]:    ** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ )

[^5]:    ** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ )
    ${ }^{\Delta}=$ frequency of laboratories $\quad N A=$ no data retumed by a ny laboratory for spec ified marker

[^6]:    ** HIV status: N=Negative; Positive --- L=Low CD4 ct ( $<200$ ), M=Moderate CD4 ct ( $>200$ but $<500$ ), H=High CD4 ct ( $>500$ ) ${ }^{\wedge}=$ frequency of laboratories
    $N A=$ no data retumed by any laboratory forspecified marker

[^7]:    
    ${ }^{\Delta}=$ frequency of laboratories
    NA = no data retumed by any laboratory for specified marker

